Law Of The Circulation Of Narcotic Drugs

Original Language Title: Gesetz über den Verkehr mit Betäubungsmitteln

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now

Read the untranslated law here: http://www.gesetze-im-internet.de/btmg_1981/BJNR106810981.html

Law on the marketing of narcotic drugs (Narcotics Act - BtMG) BtMG Ausfertigung date: 28.07.1981 full quotation: "Narcotic Drugs Act as amended by the notice of 1 March 1994 (BGBl. I p. 358), most recently by article 2 of the Act of May 20, 2015 (BGBl. I p. 725) has been changed" stand: Neugefasst by BEK. v. 1.3.1994 I 358;
 
As last amended by article 2 G v. 20.5.2015 I 725 for details on the stand number you see in the menu see remarks footnote (+++ text detection from validity: 1.8.1981 +++) (+++ requirements due to EinigVtr no longer to apply pursuant Article 109 No. 4 alia c DBuchst. aa G v. 8.12.2010 I 1864 mWv 15.12.2010 +++) (+++ official note of the standard authority on EC law: attention EGRL 34/98 (CELEX Nr: 398 L 0034) notification of EGRL of 98 at the 34 (CELEX Nr)) : 31998 L 0034 cf. V v. 18.5.2015 I 723 +++) the law as article 1 of the G v. 28.7.1981 I 681 of the Bundestag with the consent of the Federal Council decided. It's the 1.1.1982 accordance with article 7 para 1 d. Gzur reorganization d. of narcotics law v. 28.7.1981 Federal Law Gazette I p. 681, 1187 came into force.
Provisions which authorize the adoption of legal regulations, occur pursuant Article 7 para 1 d. G for the redesign of d. of narcotics law v. 28.7.1981 Gazette I p. 681, 1187 on the day after the proclamation in force. The G was announced on the 31.7.1981.

Table of contents the first section definitions section 1 narcotics section 2 other terms second section permission and permission practices § 3 permission to transport narcotics section 4 exemptions from the permit requirement section 5 refusal of permission § 6 expertise section 7 request section 8 decision article 9 restrictions, limit, terms and conditions § 10 withdrawal and revocation Article 10a permission for operation of drug consumption rooms third section obligations in section 11 narcotics traffic import, export and transit § 12 tax and acquisition section 13 prescribing and dispensing on prescription § 14 labelling and advertising, section 15 precautionary measures section 16 destruction § 17 records article 18 messages § 18a bans fourth section monitoring § 19 implementing authority section 20 special clearance for the voltage or defense case § 21 participation other authorities section 22 monitoring measures article 23 sampling section 24 Duldungs - and duty § 24a display of the cultivation of industrial hemp section 25 fees and expenses fifth section regulations authorities section 26 Bundeswehr, German Federal Police, riot police and civil protection section 27 appointments and information section 28 annual report to the United Nations sixth section offences and offences section 29 offences § 29a offences section 30 offences section 30a offences paragraph 30 b offences section 30 c capital punishment § 31 penalties or reticle penalty § 31a reticle the pursuit of § 32 offences section 33 of advanced foreclosure and forfeiture article 34 management supervisory seventh section Betäubungsmittelabhängige offenders § 35 deferral of enforcement of section 36 credit and suspended to the suspended section 37 reticle the pursuit of § 38 young people and adolescents eighth section of transitional and final provisions article 39 transitional article 39a of the transitional arrangements from occasion of the law amending drug-legal and other provisions of section 40 and paragraph 40a (void) § 41 (dropped out) first section § 1 definitions (1) narcotics in the meaning of this Act are narcotics the substances listed in annexes I to III and preparations.
(2) the Federal Government is authorized, after consultation of experts by decree with the consent of the Federal Council to change annexes I to III or supplement, if this 1 according to scientific knowledge due to the effect of a substance, especially in terms of eliciting a dependency, to be able to produce narcotic 2. because of the possibility, of a fabric or using a substance , or 3 for safety or for controlling the movement of narcotic drugs or other substances or preparations because of the extent of abuse and because of the direct or indirect danger to health is required. In the Ordinance pursuant to sentence 1 individual substances or preparations all or part of the application of this Act or a regulation adopted on the basis of this Act can be excluded, as far as the security and narcotics traffic control be ensured.
(3) the Federal Ministry of health is authorized in urgent cases to the security or narcotics traffic control by Decree without the consent of the Bundesrat substances and preparations that are not medicines, in the systems I to III to absorb, if this is necessary due to the extent of abuse and because of the direct or indirect danger to health. A regulation adopted on the basis of that provision occurs after one year out of power.
(4) the Federal Ministry of health (Ministry) will be authorized by Decree without the consent of the Federal Council to modify annexes I, III or the regulations adopted on the basis of this act as far as that on the basis of amendments to annexes to the single Convention on Narcotic Drugs 1961 as amended by the notice of February 4, 1977 (BGBl. II p. 111) and the Convention on psychotropic substances 1971 (BGBl. 1976 II p. 1477) (International addiction fabric Convention) binding for the Federal Republic of Germany in their Version is required.

§ 2 other terms (1) the meaning of this law is 1 fabric: a) chemical elements and chemical compounds, as well as naturally occurring mixtures and solutions, b) plants, algae, fungi and lichens, as well as their parts and ingredients in processed or unprocessed state, c) animal body, also live animals, as well as body parts, components and metabolites from humans and animals in processed or unprocessed state, d) micro-organisms including viruses and their components or metabolites;
2. preparation: Regardless of their physical state a mixture of fabric or the solution of one or more substances, other than the naturally occurring mixtures and solutions;
3. excluded preparation: a preparation described in annexes I to III, which is wholly or partly excluded from the narcotics regulations;
4. manufacture: win, making, preparing, loading or processing, cleaning and convert.
(2) every other movement into or out of the scope of this Act shall be equivalent to the import or export of anesthetic.
Second section permission and permission practices § 3 permission to transport Narcotics (1) a permit of the Federal Institute for medicines and medical devices needed who grow 1 narcotics, produce, trade with them, them, without trade with them, introduce, run, make, sell, bring in the traffic, purchase or 2. exempt preparations (§ 2 para 1 No. 3) wants to produce.
(2) a permit for the narcotic drugs referred to in annex I may grant only exceptionally to scientific or the other public interest purposes the German Federal Institute for drugs and medical devices.

§ 4 exemptions from the permit requirement (1) a permit according to § 3 who 1 is not required, in the context of the operation of a public pharmacy or a hospital pharmacy (pharmacy) a) in Appendix II or III designated narcotics or there made preparations manufactures, b) in Appendix II or III designated narcotics purchases, c) in annex III gives designated narcotics due to medical, dental or veterinary prescription , d) in Appendix II or III returns designated narcotics to holders of a permit to acquire of this narcotic or emits to the successor in the operation of the pharmacy, e) in annex I, II or III accepts designated narcotics to the investigation, to transfer to a body authorized to investigate narcotics or to destroy or f) in Appendix III referred to opioids in the form of finished medicinal product in transdermal or transmucosaler dosage form at a pharmacy to meet the non-postponable narcotics needs of a community powered Palliative patients are off, when the receiving pharmacy narcotic drugs not in stock, 2. narcotic drugs referred to in the context of the operation of a veterinary medicine cabinet in annex III in the form of finished medicinal product a) for an animal treated by him together, mixed with other medicinal or non-pharmacologically active components to the purposes of the application of it or for the immobilization of a Zoo - treated by him and wild - animal enclosure , b) acquires, c) for an animal treated by him or mixtures according to letter a for the immobilization of Zoo - treated by him, wild and compound animal gives off or d) to holder who returns permission to acquire of this drug or the successor operation gives the veterinary medicine cabinet 3 in Appendix III narcotics described a) on the basis of medical, dental, or veterinary prescription , b) to be applied to an animal by a person who treats this animal and operates a veterinary medicine cabinet, or c) acquires a doctor according to § 13 paragraph 1a sentence 1, 4.
Narcotic drugs referred to in annex III a) as a doctor, dentist or veterinary surgeon in the framework of cross-border services or b) has acquired on the basis of medical, dental, or veterinary prescription and it performs as travel demand or introduces, 5 Professional a) is involved in the Narcotics traffic in the transport of narcotics between authorised participants or accepts the warehousing and storage of narcotic drugs in connection with such promotion or for an authorized participant at the Narcotics traffic or b) the shipment of narcotics between authorised participants at Narcotics traffic concerned by others or gives or described as subject or patient in the context of a clinical trial or in cases of hardship number 6 of the German medicines Act in conjunction with article 83 of Regulation (EC) 6 in annex I, II or III narcotic under § 21 paragraph 2 No. 726 / 2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1) acquires.
(2) a permit according to § 3, not federal and State authorities for the scope of its official activities, as well as the authorities appointed by them with the study of narcotic drugs require.
(3) a person who pursuant to paragraph 1 Nos. 1 and 2 of no permission is needed and wants to take part in the narcotics trade, has to show this to the Federal Institute for drugs and medicine products previously. The ad must contain: 1 the names and the addresses of the display as well as the pharmacy or veterinary medicine cabinet, 2. the date of issue and the issuing authority of the pharmacy-legal permit or the approval as a veterinarian, and 3. the start date of the participation in the traffic of narcotics.
The Federal Institute for drugs and medical devices the Supreme authority of the country shall immediately inform of the content of the advertisements, as far as they relate to veterinary pharmacies of House.

Article 5 refusal of permission (1) is permission according to § 3 to fail when 1 there is no guarantee, that in the establishment and, if further operations in non-contiguous communities exist, a person is appointed in any of these operations, which is responsible for compliance with the Narcotics Law and the orders of monitoring authorities (responsible); the applicant can even place a responsible take 2 who do not have the required expertise has provided responsible or which obligations whether can not ever meet him, there are 3 facts, which concerns the reliability of the officer of the applicant, his legal representative or if the legal entities or not incorporated associations of persons authorized by law, statute or memorandum to the representation or management arising , 4. suitable rooms, facilities and fuses for the participation in the traffic of narcotics or the manufacture of exempted preparations do not exist, 5 which is not guaranteed security, narcotics traffic control or reasons referred to in manufacturing exempted preparations other than those in paragraphs 1 to 4, 6 the nature and the purpose of the requested traffic with the purpose of this law , to ensure necessary medical care of the population, but the abuse of narcotic drugs or making abusive exempted preparations as well as the occurrence or getting a narcotic dependency to exclude as much as possible, consistent or 7 on complaint of the submitted application documents not the remedy is a deficiency within the time limit (§ 8 par. 2).
(2) the permission can be refused if it precludes the implementation of international conventions of addiction substance or decisions, orders or recommendations of intergovernmental bodies of the addictive substance control or if this is necessary due to acts of the institutions of the European Union.

§ 6 expertise (1) proof of the required expertise (provided § 5 para 1 No. 2) 1 in the case of manufacturing of narcotic drugs or preparations excluded, the medicines are 2. in the case of manufacturing of narcotic drugs that are not medicines, by the certificate of a completed scientific studies of biology, by demonstrating the expertise according to article 15, paragraph 1, of the medicines Act, , chemistry, pharmacy, human or veterinary medicine stored testing and testing specified by the confirmation of at least one year practical activity in the manufacture or testing of drugs, 3. in the case of use for scientific purposes by the certificate of a completed scientific studies of biology, chemistry, pharmacy, human or veterinary medicine and 4. in all other cases by the testimony about a completed vocational training as a merchant in the wholesale and foreign trade in the areas of chemistry or Pharma and the confirmation of at least one year practical activities in narcotics traffic.
(2) the Federal Institute for drugs and medicine products may differ in individual cases on the expertise requirements referred to in paragraph 1, if the security and control of narcotics traffic or the manufacture of exempted preparations are guaranteed.

§ Application which is applying for a licence pursuant to section 3 to 7 in duplicate at the Federal Institute for drugs and medical devices that send a copy of the Supreme Land authorities. Following particulars and documents must be attached to the request: 1. the name, given name or business name and the address of the applicant and the persons in charge 2. for those the evidence of the required expertise and statements about whether, and on the basis of which circumstances they can meet the obligations incumbent on them constantly, 3. a description of the location of the premises to place (any name) , Street, house number, building and part of the building and the construction of the building, 4. a description of the existing safeguards against the taking of narcotic drugs by unauthorised persons, 5. the kind of narcotics traffic (§ 3 para 1), 6 the kind and the estimated annual quantity of produced or needed narcotic drugs, 7 in the case of creating (§ 2 para 1 No. 4) of narcotic drugs or preparations made from a brief description of the production hall, stating the nature and quantity of the raw materials or preparations , the intermediate and final products, even if raw materials or preparations, intermediate or final products are no narcotic drugs; not sectioned preparations in addition the weight percentages, in sectioned preparations the weight amounts of narcotic drugs contained per separated form and 8 in the case of using scientific or the other public interest purposes a clarify of the pursued purpose with reference on relevant scientific literature.

§ 8 decide decision (1) that to German Federal Institute for drugs and medicine products three months after receipt of the request to grant the permission. It shall immediately inform the Supreme authority of the country of the decision.
(2) the Federal Institute for drugs and medical devices the applicant gives opportunity to remedy defects of the application, so inhibited the deadline referred to in paragraph 1 until the deficiencies or the expiration of the time limit to remedy the defects. The inhibition begins with the day the call to remedy the shortcomings will be sent to the applicant.
(3) the holder of the permit has any change in the information referred to in § 7 immediately notify the Federal Institute for drugs and medical devices. If an extension as to the nature of the narcotics or narcotics traffic and changes in the person of the holder of the permit or the location of the premises, except inside a building, a new permit to apply for. The permission is changed in the other cases. The Supreme authority of the country is immediately informed about the amendment of the permit.

§ 9 limitations, limit, terms and conditions (1) permission is to restrict to the security and control of narcotics traffic or the manufacture of exempted preparations to the necessary extent. She must govern in particular: 1. the nature of the Narcotics and the Narcotics traffic, 2. the estimated annual quantity and structure on Narcotics, 3. the location of the premises and 4 thereby incurred the production run and the output, intermediate and finished products, even if they are not narcotics.
(2) the permission can 1 be limited, issued with conditions or requirements connected with be 2. after the date of their issue in terms of paragraph 1 sentence 2 changed or with other restrictions or conditions,
If this is necessary for the safety or control of narcotics traffic or the manufacture of exempted preparations or preclude the permission of implementing the International addiction fabric conventions or intergovernmental decisions, orders or recommendations facilities of the addictive substance control this is necessary due to acts of the institutions of the European Union.

§ 10 withdrawal and revocation (1) that permission can also be revoked if it within a period of two calendar years no use has been made. The period may be extended if a legitimate interest is made credible.
(2) the Supreme authority of the country is informed immediately of the withdrawal or revocation of the permit.

Article 10a permission for operation of drug consumption rooms (1) a permit of the Supreme Land authorities needed, who wants to operate a facility, in whose premises Betäubungsmittelabhängigen an opportunity to the consumption of accompanying, non-prescribed drugs is gives or grants (drug consumption room). A permit can only be granted if the State Government has regulated the conditions for issuing a legal regulation in accordance with paragraph 2.
(2) the provincial governments be empowered to regulate the conditions for the granting of a permit by a regulation referred to in paragraph 1. The regulations must specify in particular the following minimum standards for the security and control of the consumption of narcotic drugs in drug consumption rooms: 1 appropriate factual facilities of the rooms of that serve as drug consumption room;
2. ensuring a ready supply of medical emergency;
3. medical advice and assistance for the purpose of reducing the risk of consumption of narcotic drugs carried by dependent;
4. mediation of secondary and exit-oriented offers of counselling and therapy;
5. measures for the prevention of offences under this Act in drug consumption rooms, apart from the possession of narcotic drugs according to section 29, subsection 1, sentence 1 No. 3 for own consumption in small quantities;
6 required forms of cooperation with the local authorities responsible for public safety and order, to prevent crime in the immediate vicinity of the drug consumption rooms as much as possible;
7. determine of the circle of authorized users of drug consumption rooms, in particular with regard to their age, the nature of the Narcotics led to and tolerated consumption patterns; obvious primary or occasional users are to exclude from use;
8. a documentation and evaluation of work in the drug consumption rooms.
9 permanent presence of personally reliable personnel in sufficient numbers, that is professionally designed for compliance with the requirements referred to in paragraphs 1 to 7;
10. naming of a qualified person who is responsible (responsible) and can constantly fulfill the obligations for compliance with the requirements referred to in points 1 to 9, the conditions of the permit authority as well as the rulings of the monitoring authority.
(3) § 7 shall apply for the permission procedure set 1 and 2 No. 1 to 4 and 8, § § 8, 9 (2) and § 10 according to; This Supreme National Authority, in the place of the Supreme authority of the country enters the Federal Institute for drugs and medical devices at the point of the Federal Institute for drugs and medicine products each each.
(4) a permit does not entitle the staff involved in a drug consumption facilities referred to in paragraph 1 the carried narcotic substance analysis or to provide active assistance for the direct consumption of the Narcotics led to.
Third section duties in narcotics traffic § 11 wants to (1) who introduce import, export and transit to narcotic drugs in individual cases or run, needs to do this in addition to the required permission according to § 3 of a permit of the Federal Institute for drugs and medical devices. Narcotics are allowed by the territorial scope of this Act only under customs supervision without further than the stay due to the transport or envelope and without having the drugs at any time is the operator or a third person actually available during the removal, should be performed. Exempt preparations may be not carried out in countries, which have banned the imports.
(2) the Federal Government is authorized to regulate the procedure for the granting of approval by Decree without the consent of the Federal Council and to adopt rules on the import, export and transit, insofar as it is necessary for safety or control of narcotics traffic, for the implementation of the International Convention of addiction substance or of acts of the institutions of the European Union. In particular 1 can import, export or transit on certain drugs and quantities limited in or by certain countries or certain countries banned 2. derogations from paragraph 1 for travel and approved the dispatch of samples in the context of international cooperation, 3. regulations concerning the carriage of narcotic drugs by doctors, dentists, and veterinarians in the context of cross-border services hit and 4th form , Content, production, output and storage of official forms to be used are laid down.

§ 12 delivery and acquisition (1) Narcotics may be placed only on 1 persons or associations of persons which in possession of a permit according to § 3 to acquire or operate a pharmacy or veterinary pharmacy, 2. the authorities referred to in section 4 subsection 2 or § 26 or institutions, 3. (dropped out), (2) the issuing has the Federal Institute for drugs and medical devices, except in the cases of § 4 para 1 No. 1 letter e any individual submission stating of the acquirer and the type and Amount of anesthetic to report. The purchaser shall acknowledge receipt of the narcotic drugs the transferor.
(3) that paragraphs 1 and 2 do not apply when 1 dispensing of narcotic drugs referred to in annex III a) due to medical, dental or veterinary prescription in the context of the operation of a pharmacy, b) within the framework of the operation of a veterinary medicine cabinet for an animal treated by the operator of this Selfcare, c) by the doctor according to § 13 paragraph 1a sentence authorities referred to in 1, 2. the export of narcotic drugs and 3. tax and acquisition of narcotics between the in section 4, paragraph 2 or article 26 or Facilities.
(4) the Federal Ministry of health is authorized to regulate the procedure of the message and the receipt by Decree without the consent of the Federal Council. It can be regulated in particular their form, content and storage as well as an electronic transmission.

§ 13 narcotic drugs referred to in annex III prescription and dispensing on prescription (1) may only be doctors, dentists and veterinarians and only prescribed or administered as part of a medical, dental or veterinary treatment including medical treatment of narcotic dependence or another for immediate consumption or after paragraph 1a sentence 1 left to be, if their application of the or is rooted in the human or animal body. The application is particularly not justified if the intended purpose in some other way can be achieved. The narcotic drugs referred to in annexes I and II may be not prescribed, administered or leave another for direct consumption or after paragraph 1a sentence 1.
(1a) not postponable narcotics needs an outpatient powered palliative patients the doctor may leave this required for this purpose, referred to in annex III narcotic drugs in the form of finished medicinal product only, as far as and as long as the needs of the patient; not in time are covered by a prescription the maximum transfer amount shall not exceed the three-day requirement. The needs of the patient may in time be covered by a prescription, if the required narcotic drugs 1 at an in-service pharmacy within the same group or same district-free city or into each other neighboring districts or county-level cities is not in stock or ready in time to submit or 2 even though it is in stock or would be ready in time to submit in a pharmacy at number 1 , by the patient or the patient serving people not obtained in good time are can, because a) these persons must provide the patient on the spot or due to their restricted performance unable the narcotic drugs to procure, or b) is the patient on the basis of the nature and the extent of his disease to not even capable of and there are no people , which provide patients.
The doctor must be pointing out that a situation exists pursuant to sentence 1, an in-service pharmacy pursuant to sentence 2 number 1 before hiring ask, whether the required drugs is there in stock or when it is ready to submit. About the existence of the prerequisites pursuant to sentences 1 and 2 and the request pursuant to sentence 3, the doctor must maintain at least the following records and expected this three years, by the transfer of narcotic drugs to be kept: 1 the patient's name and the place, the date and the time of treatment, 2. the name of the Pharmacy and the pharmacist contacted or to his representative authorized person , 3 the name of the requested drug, 4. specifying the pharmacy, whether the drug at the time of the request is in stock or that when it is to make ready, 5. the information on those facts, from which the existence of the prerequisites pursuant to sentences 1 and 2 results.
On the request of a physician pursuant to sentence 1, whether a specific drug is in stock or until when it is ready to submit, the pharmacist must or the person entitled to its representation at least the following records do and keep these three years from the date of the request to count,: 1. the date and time of the request, 2. the name of the physician, 3. the name of the requested drug , 4. specifying versus the doctor whether the drugs at the time of that request is available or when it is ready to submit.
In the case of the Überlassens pursuant to sentence 1, the doctor has to clarify outpatient powered palliative patients or present to whose care third parties on the proper application of licensed narcotic and handed over a written instructions relating to the single and day gift.
(2) the narcotic drugs prescribed pursuant to paragraph 1 may be placed only in the context of the operation of a pharmacy, and upon presentation of the prescription. Sentence 2 must be placed only by the pharmaceutical entrepreneur and only recognised pursuant to paragraph 3 number 2a on presentation of the prescription diamorphine. In the context of the operation of a veterinary medicine cabinet may be placed only narcotic drugs referred to in annex III and animal treated only for use in one of the operators of the medicine cabinet.
(3) the Federal Government is authorized by decree with the consent of the Federal Council the prescribing of the drugs referred to in annex III, their distribution on the basis of a prescription and record their fate and the stock at doctors, dentists, veterinarians, in pharmacies, veterinary pharmacies of House, hospitals, veterinary clinics, retirement and nursing homes, hospices, facilities of the specialized outpatient palliative care, equipment of rescue services, facilities, undergoing a treatment with the substitution substances diamorphine , and to regulate, at Kauffahrteischiffen as far as it is necessary for safety or control of narcotics traffic. In particular, can 1 prescribing certain preparations, purposes, or quantities limited, 2. prescribing by means of substitution for drug addicts from complying with minimum requirements for the qualification of prescribing doctors made dependent and the laying down of minimum transferred the medical associations, 2a.
approved prescribing diamorphine only in facilities where a permit has been issued by the competent authority of the country, 2B. the minimum requirements for the facilities where the substitution substances diamorphine treatment will take place, set, 3 messages a) of prescribing doctors at the Federal Institute for drugs and medicine products on the prescribing of a substitution product for a patient in an anonymous form, b) the medical associations at the Federal Institute for drugs and medical devices on the doctors , which meet the minimum requirements referred to in point 2 and releases c) of the Federal Institute for pharmaceuticals and medical products to the competent monitoring authorities and the prescribing doctors of the patients already, another doctor has prescribed a substitution substances in an anonymous way, d) of the Federal Institute for pharmaceuticals and medical products to the competent authorities of countries about the doctors who meet the minimum requirements referred to in point 2 , e) of the Federal Institute for pharmaceuticals and medical products to the highest country health authorities about the number of patients prescribed a substitution substances, the number of physicians who are entitled to the prescribing of a substitution product, the number of physicians who have prescribed a substitution substances, prescribed the prescribed substitution substances and the type of bond and the type of anonymization, form and content of reports and releases , 4. form, content, creation, output, storage and return of the official form for the prescription to be used, as well as the records of the whereabouts and the stock set and 5. exception no. 1 letter c for the equipment of Kauffahrteischiffen adopted by article 4, paragraph 1.
2 point 2a apply to the procedure for the issuing of an authorisation pursuant to sentence section 7 sentence 2 number 1 to 4, article 8, paragraph 1, sentence 1, paragraph 2 and 3 sentence 1 to 3, article 9, paragraph 2 and article 10 according to. While the competent land authority, in the place of the Supreme authority of the country enters the Federal Institute for drugs and medical devices at the point of the Federal Institute for drugs and medicine products each each. The recipient must not use the transmitted data 2 No. 3 after set for another as the purpose referred to in sentence 1. The Federal Institute for drugs and medical devices is the perception of him by Regulation pursuant to sentence 2 assignments as borrowed by the federal body of the respective country; Details including the reimbursement of costs to the Federal Government are governed by agreement.

Labelling and advertising (1) In the Narcotics traffic are section 14 identify the drugs, using the abbreviations listed in the annexes. The marking has clearly legible, in German and in a lasting way to be.
(2) that marking must also contain the weight percentage 1. in raw, unrefined and not split off narcotics and narcotics split off the weight of the contained pure substance, 2. on drug containers and - if used - on the outer packages for substances and preparations not split the included amount of weight, in sectioned preparations that included number of pieces; This does not apply for storage containers in scientific laboratories, as well as for small containers for dispensing and ampoules.
(3) paragraphs 1 and 2 do not apply to storage containers in pharmacies and veterinary pharmacies of House.
(4) paragraphs 1 and 2 shall apply by analogy to the label of narcotic drugs, in catalogues, price lists, advertisements or similar printed matter intended for professionals involved in the narcotics trade.
(5) for controlled substances referred to in annex I may not be recruited. For controlled substances referred to in annexes II and III may be promoted only in circles of the industrial and commercial as well as entities and associations that operate a pharmacy or a veterinary medicine cabinet, narcotic drugs referred to in Appendix III also for doctors, dentists and veterinarians.

§ 15 safeguards who takes part in the traffic of narcotics, narcotic drugs, which are in his possession, has to be kept separately and must be secured against unauthorized removal. The Federal Institute for drugs and medicine products may order precautionary measures, as far as it is necessary to type or amount of narcotics traffic, the degree of risk or the amount of narcotic drugs.

Section 16 has at his own expense in the presence of two witnesses in a way to destroy it which excludes an even partial recovery of narcotics, as well as ensures the protection of man and the environment against the harmful effects of destruction (1) the owner of no longer capable to transport drugs. The destruction is to make a record and to keep these three years.
(2) the Federal Institute for drugs and medical devices, in the cases of § 19 para 1 sentence 3 that can the competent authority of the Member State, the owner urge, to send the drugs at his own expense to these authorities for the destruction. An owner of narcotic drugs is not available or not to determine or is its commitment to the destruction or the call for the sending of narcotic drugs in accordance with sentence 1 not within an earlier deadline of three months, the owner the authorities referred to in sentence 1 shall take the measures necessary to destroy. The owner or owners of the narcotic is obliged to release those charged with the destruction of narcotic drugs or condone the removing.
(3) sentence 1 and 3 shall apply paragraph 1 and paragraph 2, if the owner wants to eliminate unneeded drugs.

§ 17 records
(1) the holder of a permit under section 3 is required to maintain continuously following records of each access and any leaving separately for each facility and each drug: 1 the date, 2. the name or the company and the address of the supplier or the recipient or the other origin or other whereabouts, 3. the amount received or received from and the resulting inventory , 4. in the case of farming in addition the cultivated area by location and size, as well as the date of sowing, 5. in the case of an attempt to establish in addition to specifying the used or manufactured drugs, the substances subject to the Act does not or the exempt preparations type and quantity and 6 in the case of the tax of exempted preparations by the manufacturer in addition to the name or business name and the address of the recipient.
Instead of records referred to in paragraph 6, the copies of the invoices where the exempt preparations are identified, can be continuously filed after the date of the invoice.
(2) the records or quantities to be invoices are in 1 substances and preparations not split the amount of weight and 2nd in sectioned preparations the quantity.
(3) the records or invoice copies included three years, by the last record or from the last date of invoice, to be kept separately.

Article 18 notifications (1) the holder of a permit according to § 3 is obliged the Federal Institute for drugs and medical devices was to sign the respective amount for each facility and each drug separately, won 1st in cultivation, has been established stating the cultivated area by location and size, 2., broken down by source materials, 3 for the manufacture of other narcotic drugs was used, broken down by these drugs , 4. to the manufacture of not under this Act substances has been used, broken down by these substances, 5 to the manufacture of exempted preparations was used, was introduced by these preparations, 6, was executed by exporting countries, 7, broken down according to importing countries, 8 was acquired, 9 was traded, destroyed 10, 11 for other than the purposes specified by the numbers 1 to 10 has been used , broken down according to the respective purpose and 12th at the end of each calendar half year as inventory was present.
(2) the messages to be quantities are 1. substances and preparations not split the amount of weight and 2nd in sectioned preparations the quantity.
(3) the messages are no. 2 to 12 referred to in paragraph 1 the Federal Institute for drugs and medical devices until the 31 January and 31 July for the previous calendar half year and the message according to paragraph 1 to send no. 1 until January 31, for the previous calendar year.
(4) for the notifications referred to in paragraph 1, the official forms issued by the German Federal Institute for drugs and medical devices should be used.
Fourth section monitoring article 19 implementing authority (1) the Narcotics traffic, as well as the manufacture of exempted preparations is subject to monitoring by the Federal Institute for drugs and medical devices. This position is also responsible for the preparation, issue and evaluation of official forms prescribed for the prescription of narcotics. The Narcotics traffic at doctors, dentists and veterinarians, pharmaceutical companies in the event of the submission of diamorphine and in pharmacies as well as in the case of article 4, paragraph 1 number f is subject to 1(a) between pharmacies, veterinary house pharmacies, hospitals, and veterinary clinics of the monitoring by the competent authorities of the countries. This monitor also complying with the minimum standards referred to in Article 10a, paragraph 2; Powers regulated in §§ 22 and 24 are available to those charged with monitoring.
(2) the Federal Institute for drugs and medical devices at the same time is the special administrative services within the meaning of the International Convention of addiction fabric.
(3) the cultivation of industrial hemp in the sense of the letter d of the derogation to cannabis (marijuana) in annex I is subject to monitoring by the Federal Agency for agriculture and food. Article 45 paragraph 4 subparagraph 1 and the annex to the implementing Regulation (EU) No. 809 / 2014 of the Commission from 17 July 2014 laying down detailed rules for the application of Regulation (EU) No. 1306/2013 of the European Parliament and of the Council as regards the integrated administration and control system, the measures for the development of rural areas and the cross-compliance (OJ L 227 of the 31.7.2014, p. 69) in the respectively valid version shall apply mutatis mutandis. In addition you apply 2014. The Federal Agency for agriculture and food may you according to data submitted to the rules of the integrated administration and control system about the cultivation of hemp by the competent authorities of the country as well as the results in the framework of the regulations on the basic premium use THC carried out for the purpose of monitoring under this Act.

Article 20 authorized to change this law or the regulations adopted on the basis of this Act for defense purposes, by means of an Ordinance without the consent of the Federal Council. stay special clearance for the voltage or defence case (1) which is the Federal Government to ensure the medical care of the population with drugs if guaranteed the security and control of narcotics traffic or the manufacture of exempted preparations. In particular tasks of the Federal Institute for drugs and medicine products can transfer 1 adopted regulations under this Act and on the basis of this Act to the Ministry, the Narcotics traffic and the manufacture of exempted preparations to the in set 1 designated 2 special requirements adapted and 3 reports on stocks of a) Narcotics, b) exempt preparations and c) precursors required for the manufacture of narcotic drugs or preparations , even if they are not narcotics, are arranged. Under the Ordinance, also he about the sentence 2 No. 3 designated stocks designated obliges to their sale to certain persons or bodies can.
(2) the regulation referred to in paragraph 1 may be applied only in accordance with article 80a para 1 of the basic law.
(3) (dropped out) article 21 participation other authorities (1) the Federal Ministry of finance and the it certain customs offices contribute to the monitoring of the import, export and transit of narcotic drugs.
(2) the Federal Ministry of finance may in agreement with the Federal Ministry of the Interior the officials of the Federal Police, who have been entrusted, and in agreement with the Bavarian Minister of the Interior appoint officials of the Bavarian border police with the performance of tasks which are the responsibility of the Customs Office referred to in paragraph 1 with tasks of border protection pursuant to section 2 of the Federal Police Act. The officials referred to in sentence 1 shall carry out these tasks, section 67, paragraph 2, of the Federal Police Act shall apply mutatis mutandis.
(3) in the case of suspected violations of the prohibitions and restrictions of this law, resulting in the clearance, the co-operating authorities inform the Federal Institute for drugs and medical devices.

Article 22 monitoring measures (1) the persons responsible for monitoring are authorized to inspect 1 documents on the Narcotics traffic or the production or the following manufacturing placing of exempted preparations and to produce any copies or photocopies, as far as them for the security or the control of narcotics traffic or the manufacture of exempted preparations of importance can be 2. natural and legal persons and to require all necessary information not incorporated associations , 3. land, buildings, parts of buildings, facilities and means of transport, where the Narcotics traffic or exempted preparations manufacture is performed, to enter and visit with the responsible people to convince have, that complied with the rules governing trade in narcotics or the manufacture of exempted preparations. To prevent urgent threats to public safety and order, especially if a thwarting of the control of narcotics traffic or exempted preparations manufacturing is to get these facilities outside the hours of operation and business shall as well as residential purposes are entering serving rooms; in this respect, the fundamental right of inviolability of the home (article 13 of the Basic Law) is restricted. Insofar as to industrial manufacturing and wholesale businesses, the visits are carried out as a rule every two years 4.
preliminary arrangements to meet, as far as it is necessary for the prevention of urgent threats to the security or the control of narcotics traffic or the manufacture of exempted preparations. For the same purpose, they may fully or partially prohibit the continued participation of the Narcotics traffic or the further manufacture of exempted preparations and take the drugs stocks or stocks of gutted preparations under official wraps. The competent authority (§ 19 para 1) has to decide within one month after the adoption of the provisional measures on this.
(2) the competent authority may order measures pursuant to paragraph 1 Nos. 1 and 2 also in writing.

§ To 23 sampling (1) as far as it is necessary for the implementation of the provisions on trade in narcotics or the manufacture of exempted preparations are monitoring people commissioned entitled, request samples against receipt after its selection for the purposes of the investigation or to remove. Unless expressly indicated is not a part of the sample is or, unless the sample not or without danger to the purpose of the investigation not into parts of equal quality is divisible, leaving behind a second item of the same type as the one taken as a sample.
(2) to reduced back samples are officially seal or seal. They are to be provided with the date of sampling and the date of the day, after which the lock or seal be considered lifted.
(3) for the extracted samples, compensation is to provide, as far as not expressly waived.

Section 24 Duldungs - and duty (1) each participant at the Narcotics traffic or any manufacturer of exempted preparations is obliged to tolerate the measures pursuant to articles 22 and 23 and helping the persons responsible for monitoring in the performance of their duties, to denote places especially them on request, where the Narcotics traffic or exempted preparations manufacture takes place, building, room PISE plots, , To open containers and containers, information and to allow inspection of documents and the taking of samples.
(2) the debtor information the information on such questions, may refuse the answer himself or one of his No. 1-3 of the code of civil procedure referred to members of the danger of criminal prosecution or proceedings would expose in section 383, paragraph 1 according to the law of administrative offences.

§ 24a is indicator of the cultivation of industrial hemp cultivation of industrial hemp in the sense of the letter d of the derogation to cannabis (marijuana) in annex I to show until 1 July of the crop year in triplicate to the Federal Agency for agriculture and food to fulfill their duties according to § 19 para 3. For the display, use the official form issued by the Federal Agency for agriculture and food. The ad must contain: 1. name, the given name and address of the farmer, for legal entities the name of the company of agriculture as well as the legal representative, 2. the enterprises of agriculture by the competent professional association member allocated to / cadastral number, 3. the variety sown out accompanied by the official labels, as far as this not have been provided under the rules of the base premium of the competent authority of the country , 4. the sowing area in hectares and AR, specifying the identification number; not exist, the cadastral number or other identifying the sowing area information, which have been approved by the Federal Agency for agriculture and food, can be specified such as municipal area, Hall and floor piece.
The Federal Agency for agriculture and food send a copy of the display subscribed from the applicant immediately. She also must send a copy of the display the competent police authorities and prosecutors at their request, when this is necessary for the prosecution of offences under this Act. There are indications of the Federal Agency for agriculture and food, that the cultivation of industrial hemp is not the requirements of the letter d of the derogation to cannabis (marijuana) in annex I, it informs the locally competent public prosecutor's Office.

Article 25 fees and expenses (1) the Federal Institute for drugs and medicine products rises for its individually attributable public services according to this law and the regulations issued on the basis of this Act fees and expenses.
(2) the Federal Ministry is authorised to determine the chargeable offences by means of an Ordinance without the consent of the Federal Council and to see this fixed rates, or frame rates.
Fifth section regulations authorities section 26 Bundeswehr, German Federal Police, riot police and civil protection (1) this law does with the exception of rules relating to the approval under section 3 to facilities that serve the Narcotics supply of the German armed forces and the Federal Police, as well as stockpiling to plant II or III designated narcotics for the civil protection application.
(2) in the areas of the German armed forces and the Federal Police, the enforcement of this Act and the Narcotics traffic monitoring incumbent the relevant competent authorities and experts of the German armed forces and the Federal Police. The implementation of this law is the for the Sanitätsmaterialbevorratung of competent national and regional authorities in the field of civil protection.
(3) the Ministry of defence may allow exceptions to this law and the regulations issued on the basis of this Act for its Division in consultation with the Ministry in some cases, as far as the International addiction fabric Convention do not preclude the and require this compelling reasons of the defence.
(4) this Act applies appropriate with the exception of the provisions relating to the approval under section 3 on facilities that serve the Narcotics supply of standby police forces of the countries.
(5) (dropped out) § 27 appointments and information (1) the Federal Criminal Police Office reports the Federal Institute for drugs and medicine products per year until March 31 for the previous calendar year the known seizures of drugs by type and quantity, as well as, where appropriate, further he use of the narcotics. The name or business name and the address of the purchaser shall be indicated in the case of recovery.
2. the authorities referred to in article 26 shall have to inform the Federal Institute for drugs and medical devices, as far as it is necessary for the implementation of the International Convention of addiction substance on the circulation of narcotic substances in their areas.
(3) in criminal proceedings, which have offences under this Act to the subject, are to deliver 1 to monitor and control of the movement of narcotics at the section 19, subsection 1, sentence 3 has been the final decision with justification, if on a sentence or a detention order of improvement and assurance identified persons and institutions of the competent authority of the country or is acquitted the defendant because of inability to blame , 2. to fulfil the tasks referred to in article 19, paragraph 1, sentence 2 the Federal Institute for drugs and medical devices in the case of the survey of the public action against doctors, dentists and veterinarians a) the indictment or a claim its place, b) the application for a Strafbefehls and c) the decision concluding the procedure ground; is been discarded with this decision an appeal or in the contested decision reference is made to, also it must be to convey.
The resubmitted the Strafvollstreckungs - or the law enforcement agency.
(4) the decision concluding the procedure ground in other criminal cases shall be the competent authority country, if there is a connection of the crime with the Narcotics traffic and the knowledge of the decision from the perspective of the transmitting site for Narcotics traffic monitoring is required; Paragraph 3 sentence 1 No. 2 letter c second half-sentence, shall apply mutatis mutandis.

Section 28 annual report to the United Nations (1) the Federal Government shall annually by June 30 for the previous calendar year the Secretary-General of the United Nations an annual report on the implementation of the international conventions of addiction substance a form adopted by the Commission on Narcotic Drugs of the United Nations. The competent authorities of the countries involved in the preparation of the report and submit their papers to the Federal Institute for drugs and medical devices until March 31 for the previous calendar year. As far as it can be determined, the information required in the form they are appreciated.
(2) the Federal Government is authorized to determine to have who and what make appointments, namely statistics, other information and information, which are necessary for the implementation of the International Convention of addiction substance by decree with the consent of the Federal Council. In the Regulation provisions concerning the manner, the shape, the time and the recipient of the messages can be taken.
Sixth section offences and offences section 29 offences (1) with imprisonment up to five years or will be punished with fines, who illegally grows 1 narcotics, manufactures, trade drives with them, she, without commercial introduces to drive, performs, sold, emits, otherwise brings into circulation, acquires or otherwise 2. one gained, exempted preparation (§ 2 para 1 No. 3) establishes without permission according to § 3 para 1 No. 2 , 3. narcotics has 4 (dropped out), without being in possession of a written permit for acquiring at the same time, 5. contrary to section 11, subsection 1, sentence 2 narcotics performs, 6 contrary to article 13, paragraph 1 a narcotic) prescribes, b) administered or for direct consumption leaves 6 a.
contrary to § 13 paragraph 1a sentence 1 and 2 a there called narcotic leaves, 7 violates article 13, paragraph 2 a) narcotic drugs in a pharmacy or veterinary pharmacy, b) diamorphine when pharmaceutical company delivers, advertises 8 contrary to § 14 para 5 for narcotic drugs 9 incorrect or incomplete information makes, to gain for himself or another or for an animal a drug prescription , an opportunity to the unauthorized acquisition or unauthorized supply of narcotic drugs gives another 10 a, granted, one such opportunity stating publicly or selfish or one other unauthorized consumption of narcotics convincing 11 without permission in accordance with section 10a gives someone else an opportunity to the unauthorized consumption of narcotic drugs or granted, or who is a outside a facility after such a self-serving consumption opportunity existing section 10a or publicly communicated , 12 public, urges in a meeting or through dissemination of writings (section 11 subsection 3 of the Penal Code), to consume narcotic drugs, the not permissibly are prescribed, 13 funds or other assets another for an illegal act according to numbers 1, 5, 6, 7, 10, 11 or 12 14 a regulation according to § 11 paragraph 2 sentence 2 provides, no. 1 or § 13 para 3 sentence 2 No. 1 that contravenes 2a or 5, so far as it refers to this regulation for a specific offence.
Providing sterile syringes at Betäubungsmittelabhängige and the public information about it are no gain and no public parts with an opportunity for consumption pursuant to sentence 1 No. 11 (2) in the cases of paragraph 1 sentence 1 No. 1, 2, 5 or 6 point (b) is liable to prosecution.
(3) in especially serious cases, the penalty is imprisonment not less than one year. A particularly serious case usually exists when the perpetrator 1. in the cases of paragraph 1 Professional is sentence 1 No. 1, 5, 6, 10, 11 or 13, 2nd by a 1 No. 1, 6 or 7 designated set of in paragraph 1 actions endangered the health of several people.
(4) the perpetrators in the cases of paragraph 1 is sentence 1 No. 1, 2, 5 and 6 point (b), no. 10 or 11 negligence, the penalty is imprisonment up to one year or a fine.
(5) the Court may refrain 2 and 4 from punishment referred to in paragraphs 1, if the perpetrators grow narcotic drugs only for their own consumption in small quantities, manufactures, introduces, runs, performs, acquires, gained in any other way, or has.
(6) which set rules of paragraph 1 1 No. 1, so far as they concern the trade, give away or sell, also apply if the action refers to substances or preparations, which are not narcotic, but are issued as such.
Footnote section 29, subsection 1, sentence 1 No. 1, 3, 5: in accordance with the formula in the decision with the GG compatible gem. BVerfGE v. 9.3.1994 I 1207-2 BvL 43/92 and others - section 29a (1) crimes punishable by not less than one year shall be punished, who over 21 years has 1 as a person narcotic drugs without permission to a person under 18 years of age or she administered her contrary to section 13, paragraph 1, or for direct consumption leaves or 2 with narcotic substances in a quantity of not less illicit trade drives, in no small amount produces or emits or has it, without to have obtained on the basis of a permit according to § 3 para 1.
(2) in less serious cases, the punishment is imprisonment from three months up to five years.

Section 30 will be punished (1) offences punishable under two years, who illegally grows 1 narcotics, manufactures or trade is driving with them (section 29, subsection 1, sentence 1 No. 1) and this as a gang member, which is the continued Commission of such acts has joined, 2. in the case of § 29a 1 Professional is no. 1, 3. are off narcotic administered another leaves for direct consumption, or by lightly caused his death or 4. narcotic in a quantity of not less unauthorized imports.
(2) in less serious cases, the punishment is imprisonment from three months up to five years.
Footnote § 30 para. 1 No. 4: compatible in accordance with the formula in the decision with the GG ACC.. BVerfGE v. 9.3.1994 - 2 BvL 43/92 and others - section 30a is punished (1) offences punishable under five years, who illicitly builds narcotic drugs in no small amount, manufactures, trade drives with them, she or running (section 29, subsection 1, sentence 1 No. 1) and acts as a gang member , which has combined for the continued Commission of such acts.
(2) likewise is who 1 as a person over 21 years determines a person under 18 years of age with narcotic drugs without permission to trade without to trade, to introduce, perform, sell, to dispose of or otherwise in the traffic to bring them, or to promote one of these actions, unauthorized trading drives 2 with narcotics in no small amount or punished, without trading , introduces, running or gained and leads with a firearm or other objects, which are suitable for the injury of persons and determine their nature.
(3) in less serious cases, the punishment is imprisonment from six months up to ten years.

§ 30B offences article 129 of the Penal Code also applies, if there is an association whose purposes oder whose activity on the unauthorized distribution of drugs within the meaning of § 6 No. 5 of the Penal Code are directed, not or not only domestically.

section 30 c to be applied to capital punishment (1) in the cases of § 29 par. 1 No. 1, 5, 6, 10, 11 and 13 is section 43a of the Penal Code. This does not apply as far as the offender without trade with them, sold narcotics, has, acquires, or gained in any other way.
(2) in the cases of § 29a, 30, 30a and 30B section 43a of the Penal Code shall apply.

§ 31 according to article 49, paragraph 1, of the criminal code reduce the penalty penalties or reticles of punishment that court may or, if the offender has forfeited any prison sentence of more than three years, refrain from punishment if the perpetrator 1. by voluntary reveal of his knowledge has significantly helped, that an offence under sections 29 to 30a, which stands with his act in connection that could be uncovered, or 2. voluntarily his knowledge in good time so that a criminal offence according to § 29 para 3, § 29a para 1, § 30 par. 1, article 30a, paragraph 1 which stands with his act in the context and he knows of their planning, revealed a service center, still can be prevented.
The perpetrator in the Act was involved, his contribution to the education must extend 1 point 1 of the own participation to set. § applies 46 b para 2 and 3 of the Penal Code.

§ 31a has reticle the pursuit of (1) the procedures an offence according to article 29, paragraph 1, 2 or 4 on the subject, as can the Prosecutor from pursuing refrain, the guilt of the offender as low to look at would be no public interest in the prosecution and the offender based narcotic drugs only for their own consumption in small quantities, produces, imports, performs, performs, acquires that gives or has in any other way. The tracking should be waived if the offender in a drug consumption room has narcotic only for own consumption, can be tolerated according to sec. 10a, in small quantities, without at the same time being in possession of a written authorisation for the acquisition.
(2) the action is already raised, the Court in any position of the procedure under the conditions of paragraph 1 with the consent of the Prosecutor and the accused can adjust the procedure. The consent of the accused need not, if the trial for the reasons stated in section 205 of the code of criminal procedure cannot be performed or in the cases of § 231, paragraph 2 of the code of criminal procedure and the sections 232 and 233 of the code of criminal procedure in his absence is performed. The decision is taken by vote. The decision is not subject to appeal.

§ 32 offences (1) any person who intentionally trades or negligently 1.
contrary to section 4, paragraph 3, sentence 1 does not show the Narcotics traffic, 2nd in a request under article 7, also in conjunction with Article 10a, paragraph 3 or article 13 paragraph 3 sentence 3, false information is or not completely incorrect documentation added, 3. contrary to article 8, paragraph 3, sentence 1, also in conjunction with section 10a subsection 3, a change that is not right, or not immediately communicated , 4. an executable Edition according to § 9 para 2, also in conjunction with section 10a subsection 3, contravenes, 5. contrary to section 11, subsection 1, sentence 1 a - narcotic drugs without authorisation or running, 6 legal regulation according to § 11 paragraph 2 sentence 2 No. 2 to 4, article 12, paragraph 4, article 13, paragraph 3, sentence 2 No. 2, 3 or 4, article 20, paragraph 1 or § 28 para 2 is contrary to , insofar as it refers to this penalty provision for a particular offense, 7 contrary to article 12, paragraph 1 gives narcotics or violates article 12 par. 2 incorrectly, incompletely or not immediately reports providing or acquiring, or not acknowledged the reception, 7a.
contrary to § 13 paragraph 1a sentence 3 not, not properly or in a timely manner at a pharmacy requests, 7B. contrary to article 13 paragraph 1a a recording not, not properly or not will set of 4 or 5 or kept a record of not or not at least three years, 8 contrary to § 14 para 1 to 4 improperly features narcotics, contravenes 9 an enforceable order under section 15 set 2 , 10 contrary to article 16, paragraph 1 narcotics improperly destroyed, not produces a transcript or keep them contrary to § 16 para 2 sentence 1 submits narcotics not to destroy, also in connection with § 16 para 3, 11 contrary to article 17, paragraph 1 or 2 records do not, not properly or not fully leads or not kept records or invoice copies contrary to § 17 para 3 , 12 contrary to § 18 para 1 to 3 messages incorrectly, incompletely or not timely reimbursed 13 contrary to section 24 para 1 of a Duldungs - or obligation to cooperate does not comply with, 14 contrary to section 24a not, incorrectly, incompletely or not in time does the cultivation of industrial hemp or 15 places narcotics in a mailing, although this dispatch by the UPU Convention or a Convention of the Universal Postal Union is prohibited; Postal secrecy in accordance with article 10 para 1 of the basic law is limited in this respect for the persecution and prosecution of the offence.
(2) the offence can be punished with a fine up to twenty-five thousand euros.
(3) managing authority within the meaning of § 36 para 1 No. 1 of the code of administrative offences is the Federal Institute for drugs and medical devices, as far as the law is carried out by him, in the case of § 32 para 1 No. 14 the Federal Agency for agriculture and food.

§ 33 foreclosure and confiscation is extended (1), section 73d of the criminal code to apply 1 in the cases of § 29 para 1 sentence 1 No. 1, 5, 6, 10, 11 and 13, if the offender is professional, and 2. in the cases of § § 29a, 30 and 30a.
(2) items, a crime refers to the sections 29 to 30a or a misdemeanor according to § 32, can be withdrawn. section 74a of the Penal Code and article 23 of the code of administrative offences are to be applied.

Section 34 management supervision in the cases of § 29 para 3, which can sections 29a, 30 and 30a the court management supervision order (section 68, paragraph 1 of the Penal Code).
Seventh section Betäubungsmittelabhängige offender § 35 deferral of enforcement (1) is someone convicted of a crime to a term of imprisonment of not more than two years and is apparent from the reasons for judgment or otherwise is determined that he committed the offence on the basis of a narcotic dependency, so can reset the enforcement authority with the approval of the Court of first instance to the enforcement of the penalty, the remainder of a penalty or the detention order of the placing in a withdrawal institution for a maximum of two years , if the offender is in a serving his rehabilitation treatment due to its dependency or agrees to undergo, such and whose beginning is guaranteed. Also staying in a State-approved facility that is used to resolve the dependency or to counter a renewed dependence is considered treatment.
(2) against the refusal of the approval of the Court of first instance, the appeal is to the executing authority after the second part of the third book of the code of criminal procedure. The offender may challenge the denial of this agreement only with the rejection of the deferral by the enforcement authority after the sections 23 to 30 of the introductory act to the Judiciary Act. The Court of appeal in this case also decides on the refusal to give of consent; It can grant the consent itself.
(3) paragraph 1 shall apply accordingly, if 1 on a total prison sentence of not more than two years has been recognized or 2 on a custodial sentence or a total prison sentence of more than two years has been recognized and does not exceed a vollstreckender rest of the sentence or the total imprisonment of two years and in addition, the conditions of in paragraph 1 for their importance to most of the crime private from are met.
(4) the convicted person is obliged at times, which constitutes the executing authority, to provide proof concerning the inclusion and on the continuation of the treatment; the attending persons or institutions inform the executing authority a discontinuation of treatment.
(5) the executing authority revokes the deferral of enforcement, if the treatment is not started or discontinued and is not expected, that the offender immediately begins a treatment of same type or resumes, or if the convicted person does not provide the evidence required pursuant to paragraph 4. The revocation may be waived if the convicted person subsequently proves that he is in treatment. A withdrawal does not preclude a further deferral of enforcement pursuant to sentence 1.
(6) the deferral of enforcement is revoked also, if 1 in subsequent formation of a total penalty will be back not also their enforcement referred to in paragraph 1 in connection with paragraph 3 or 2 another against the convicted person recognized custodial sentence or custodial measure of improvement and is to enforce security.
(7) the executing authority revoked the deferral, it is empowered to issued an arrest warrant for the execution of the sentence or the accommodation in a detox facility. The decision of the Court of first instance can be brought against the withdrawal. The progress of enforcement is not inhibited by the time the Court is seised. § 462 of the code of criminal procedure shall apply mutatis mutandis.

Section 36 credits and suspended sentence to probation (1) is the enforcement has been put back and has the offender in a State-approved facility can handle, as demonstrated by the sentenced person, the time of his stay in this facility on the penalty will be applied, until as a result of the credit transfer two-thirds of the penalty are done. The decision on the eligibility will the Court at the same time with the approval according to article 35, paragraph 1. Two thirds of the penalty are done through the pretrial or a treatment at the facility at an earlier date is no longer required, so the Court suspends the enforcement of the remainder of the sentence to probation, as soon as this can be responsible for taking into account the security interest of the general public.
(2) has been made back the enforcement and has the condemned man of other than the treatment referred to in paragraph 1 being dependent on subject, so the Court suspends the enforcement of the sentence or of the remainder of the sentence suspended, as soon as this can be responsible for taking into account the security interest of the general public.
(3) as the Court has the offender undergoing after the fact of a treatment of his addiction, may order, if the conditions of in paragraph 1 sentence 1 are not available, that the time of treatment all or part of the penalty will be applied, if this is indicated, taking into account the requirements, which has been the treatment of the sentenced person.
(4) sections 56a to 56 g and 57 par. 5 sentence 2 of the Penal Code shall apply mutatis mutandis.
(5) pursuant to paragraphs 1 to 3, the Court of first instance without oral proceedings makes the decisions by decision. The executing authority, the offender and the attending persons or facilities can be heard. Immediate appeal is possible against the decisions. For the decisions taken pursuant to paragraph 1 sentence 3 and referred to in paragraph 2, section 454, paragraph 4, of the code of criminal procedure shall apply mutatis mutandis; the Court granted the instruction about the suspension of the remainder of the punishment.

§ 37 reticle the bringing of public action
(1) a suspect in suspected of having committed an offence on the basis of a drug dependency, stands and no higher penalty than imprisonment is expected up to two years, so the prosecution with the consent of the Court with jurisdiction for the main proceedings may waive temporarily the bringing of public action, if the accused proves that he is undergoing due to its dependency on the treatment referred to in article 35, paragraph 1 , and his rehabilitation is expected. The public prosecutor's Office sets dates, to which the accused to prove the continuity of the treatment has. The procedure will be continued, if 1 the treatment not up to continued their planned completion is, 2. the accused does not result in the evidence required pursuant to sentence 2, the suspect commits an offence 3. and this shows that the expectation which underlay the reticle of the survey of the public action has not complied, or to expect a custodial sentence of more than two years is 4. on the basis of new facts or evidence.
In the cases of the set of 3 No. 1, 2 may be waived by the continuation of the proceedings, if the accused subsequently proves that he is more in treatment. The Act can be traced if the procedure within a period of two years will be continued.
(2) the action is already raised, the Court with the consent of the public prosecutor's Office can set so for the time being the procedure until the end of the main hearing, in which the findings can be last approved. The decision was made by means of an unchallengeable order. Paragraph 1 sentence 2 to 5 shall apply mutatis mutandis. Also, that the procedure will not be continued is to determine a final (par. 1 sentence 5).
(3) in article 172, paragraph 2, sentence 3, article 396, paragraph 3, and § 467, paragraph 5, of the code of criminal procedure to section 153a of the code of criminal procedure apply arrangements accordingly.

Section 38 young people and adolescents (1) when sentence of youth penalty apply accordingly sections 35 and 36. There are also the consent of the legal guardian and legal representative in addition to the commitment of the young people according to article 35, paragraph 1, sentence 1. In the case of § 35 paragraph 6 sentence 2, § 83 para 2 takes no. 1, para 3 sentence 2 of the Juvenile Court Act mutatis mutandis application. By way of derogation from § 36 para 4 apply §§ 22-26a of the juvenile court act according to. For the decisions according to § 36 para 1 sentence 3 and para. 2 §§ 58 apply in addition to section 454, paragraph 4, of the code of criminal procedure, in addition to 59 paras 2 through 4 and section 60 of the Juvenile Court Act.
(2) section 37 applies mutatis mutandis for teenagers and adolescents.
Eighth section of transitional and final provisions article 39 transitional facilities in their premises, the consumption was tolerated by carried, non-prescribed drugs before January 1, 1999, may further be operated without a permit of the Supreme Land authorities only, if no later than 24 months after the entry into force of the third BtMG Amendment Act of 28 March 2000 (Federal Law Gazette I p. 302) a regulation adopted in accordance with Article 10a, paragraph 2 and permit requested according to Article 10a, paragraph 1. To the unquestionable decision on a request for these facilities continue run only, as far as the requirements according to section 10a subsection 2 or a regulation adopted pursuant to this regulation. Section 29, subsection 1, sentence 1 applies to facilities pursuant to sentence 1 No. 10 and 11.

Article 39a transitional arrangements on the occasion of the law amending drug-legal and other requirements for a person who according to § 5 paragraph 1 number 2 has no expertise, but according to article 141, paragraph 3 of the German medicines Act meets the requirements on July 22, 2009, proof of the required expertise applies according to § 6 paragraph 1 No. 1 as given.

§§ 40 and 40a (void) section 41 (dropped out) Annex I (to section 1 para 1) (narcotics ineligible to transport) (site: BGBl. I, 2001, 1180-1186; regarding the details of the changes see footnote) column 1 contains the International Nonproprietary name (INN) of the World Health Organization. Designation of the substance, the INN takes precedence over all other labels.
Column 2 contains other non-protected fabric labels (short names or common names). If there exists no INN for a substance, the name bold in this column can be used to its unique name. All other non-bold-printed labels are scientifically inconclusive. They are therefore used in conjunction with the name in column 3.
Column 3 contains the chemical name of the substance according to the nomenclature of the International Union of pure and applied chemistry (IUPAC). If no name is listed in column 1 or 2, the column 3 is to use.
 
 
 
 
 
INN other non-proprietary or common name chemical name (IUPAC) Acetorphin - {4,5α-Epoxy-7α-[(R)-2-hydroxypentan-2-yl]-6-methoxy-17-methyl-6,14-ethenomorphinan-3-yl}acetat - Acetyldihydrocodein (4, 5α-epoxy-3-methoxy-17-methyl-morph-Ibrahim 6α-yl) acetate Acetylmethadol - (6-Dimethylamino-4,4-diphenyl-heptan-3-yl) acetate - acetyl-α-methylfentanyl N-Phenyl-N-[1-(1-phenyl-propan-2-yl)-4-piperidyl]acetamid - 4-Allyloxy-3,5-dimethoxy-phenethylazan Allylprodin (3-allyl-1-methyl-4-phenyl-4-piperidyl) propionate alphacetylmethadol - [(3R,6R)-6-Dimethylamino-4,4-diphenylheptan-3-yl]acetat Alphameprodin - [(3RS,4SR)-3-Ethyl-1-methyl-4-phenyl-4-piperidyl]propionat Alphamethadol - (3R,6R)-6-Dimethylamino-4 , 4-diphenylheptan-3-ol Alphaprodine - [(3RS,4SR)-1,3-Dimethyl-4-phenyl-4-piperidyl]propionat - 5-(2-Aminopropyl)indol (5-IT) 1-(1H-Indol-5-yl)propan-2-amin Anileridin - Ethyl[1-(4-aminophenethyl)-4-phenyl-piperidin-4-carboxylat) - BDB 1-(1,3-Benzodioxol-5-yl)butan-2-ylazan Benzethidin - ethyl {1 [(2-benzyloxy) ethyl]-4-phenyl-piperidin-4-carboxylate} Benzfetamin Benzphetamin (Benzyl)(methyl)(1-phenylpropan-2-yl)azan - 1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)propan-1-on - Benzylfentanyl N-(1-Benzyl-4-piperidyl)-N-phenyl-propanamid - benzyl morphine 3-Benzyloxy-4, Betacetylmethadol 5α-epoxy-17-methyl-morphine 7-en-6α-ol - [(3S)] (,6R)-6-Dimethylamino-4,4-diphenylheptan-3-yl] Betameprodin - [(3RS,4RS)-3-Ethyl-1-methyl-4-phenyl-4-piperidyl]propionat acetate Betamethadol - (3S,6R)-6-Dimethylamino-4,4-diphenylheptan-3-ol Betaprodin - [(3RS,4RS)-1,3-Dimethyl-4-phenyl-4-piperidyl]propionat Bezitramid - 4-[4-(2-Oxo-3-propionyl-2,3-dihydrobenzimidazol-1-yl)piperidino]-2,2,-diphenyl-butannitril - 25B-NBOMe (2C-B-NBOMe) 2-(4-Brom-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamin Brolamfetamin Dimethoxybromamfetamin (DOB) (RS)-1-(4-Brom-2,5-dimethoxy-phenyl)propan-2-ylazan - Bromdimethoxyphenethylamin (BDMPEA) 4-bromo-2) , 5-dimethoxyphenethyl-azan - cannabis (marijuana, plants and parts of plants belonging to the genus cannabis) - except a) whose seed, provided that he is not destined for the illicit cultivation, b) when they grown in countries of the European Union with certified seed of varieties come on March 15 of the crop year in which article 9 of the delegated Regulation (EU) No. 639 / 2014 of the Commission from March 11, 2014, supplementing Regulation (EU) No. 1307/2013 of the European Parliament and of the Council with rules on direct payments to farmers in the framework of the common agricultural policy support schemes and amending Annex X of to that Regulation (OJ L 181 of the 20.6.2014, p. 1) in the currently valid version called common catalogue of varieties of agricultural plant species are listed, or tetrahydrocannabinol content 0.2 percent does not exceed and traffic with them (excluding the extension) is exclusively commercial or scientific purposes that exclude a misuse for noise purposes, c) if they are planted as a protective strip at beet cultivation and destroyed before flowering , d) if they are grown of companies of agriculture which meet the requirements of 1 paragraph 4 of the law on the retirement of farmers, with the exception of companies of forestry, the horticulture and viticulture, fish farming, the aquaculture, beekeeping, inland fishing and the hiking sheep farm, or for a grant of Regulation (EU) No. 1307/2013 of the European Parliament and of the Council of 17 December 2013 with rules on direct payments to farmers in the context of support schemes of the Common agricultural policy and repealing Regulation (EC) No 637 / 2008 of the Council and Regulation (EC) No 73/2009 of the Council (OJ L 347 of the 20.12.2013, p. 608) come in the amended eligible and is growing only from certified seed of varieties on 15 March of the crop year in which article 9 of the delegated Regulation (EU) No. 639 / 2014 mentioned common catalogue of varieties of agricultural plant species lists (industrial hemp) or e) for the purposes referred to in annexes II and III - cannabis resin (hashish , separate the plants belonging to the genus cannabis resin =) - Carfentanil - Methyl[1-phenethyl-4-(N-phenyl-propanamido)piperidin-4-carboxylat] Cathinon - (S) - 2-amino-1-phenyl-Propan-1-on - 2C-C 2-(4-Chlor-2,5-dimethoxyphenyl)ethanamin - 2C-D (2C-M) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamin - 2C-E 2-(4-Ethyl-2,5-dimethoxyphenyl)ethanamin - 2C-l 4-lod-2,5-dimethoxyphenethyl-azan - 6-CL-MDMA [1-(6-Chlor-1,3-benzodioxol-5-yl)propan-2-yl](methyl)azan Clonitazen -.
{2-[2-(4-Chlorbenzyl)-5-nitrobenzimidazol-1-YL]ethyl}diethylazan-25C-NBOMe (2C-C-NBOMe) 2-(4-Chlor-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamin-codeine-N-oxide 4, 5α-epoxy-3-methoxy-17-methyl-morphine 7-en-6α-ol-17-oxide Codoxim-(4, 5α-epoxy-3-methoxy-17-methyl-morph-Ibrahim-6-yliden-aminooxy) acetic acid-2 c-p 2-(2,5-Dimethoxy-4-propylphenyl)ethanamin-2C-T-2 4-Ethylsulfanyl-2,5-dimethoxy-phenetylazan-2C-T-7 2,5-Dimethoxy-4-(propylsulfanyl)phenethylazan Desomorphine Dihydrodesoxymorphin 4, 5α-epoxy-17-methyl-morph-Ibrahim-3-ol Diampromid-N-{2-[(Methyl)(phenetyl)amino]propyl}-N-phenylpropanamid-Diethoxybromamfetamin 1-(4-Brom-2,5-diethoxyphenyl)propan-2-ylazan Diethylthiambuten-Diethyl(1-methyl-3) , 3-di-2-thienylallyl) azan - N, N-Diethyltryptamin (Diethyltryptamin, DET) Diethyl[2-(indol-3-yl)ethyl]azan - dihydroetorphin (18,19-dihydroetorphin) (5R,6R,7R,14R)-4,5α-Epoxy-7α-[(R)-2-hydroxypentan-2-yl]-6-methoxy-17-methyl-6,14-ethanomorphinan-3-ol Dimenoxadol - (2-Dimethylaminoethyl)[(ethoxy)(diphenyl)acetat] Dimepheptanol Methadol 6-Dimethylamino-4,4-diphenyl-heptan-3-ol - Dimethoxyamfetamin (DMA) 1-(2,5-Dimethoxyphenyl)propan-2-ylazan - Dimethoxyethylamfetamin (DOET) 1-(4-Ethyl-2,5-dimethoxyphenyl)propan-2-ylazan - Dimethoxymethamfetamin (DMMA) 1-(3,4-Dimethoxyphenyl)-N-methylpropan-2-amin - Dimethoxymethylamfetamin (DOM (, STP) (RS)-1-(2,5-Dimethoxy-4-methylphenyl)propan-2-ylazan - Dimethylheptyltetrahydrocannabinol (DMHP) 6,6,9-Trimethyl-3-(3-methyl-octan-2-yl)-7,8,9,10-tetra-hydro-6H-benzo(c) chromen-1-ol Dimethylthiambuten - Dimethyl(1-methyl-3,3-di-2-thienylallyl)azan - N, N-DIMETHYLTRYPTAMINE (DMT, DIMETHYLTRYPTAMINE) [2-(Indol-3-yl) ethyl] dimethyl-azan Dioxaphetyl - Ethyl-(4-morpholino-2,2-diphenylbutanoat) Dipipanone - 4,4-diphenyl-6-piperidinoheptan-3-on - DOC 1-(4-Chlor-2,5-dimethoxyphenyl)propan-2-ylazan Drotebanol - 3,4-dimethoxy-17-methyl-morph-Ibrahim 6vpp, 14-dihydroxy - N-Ethylbuphedron (NEB) 2-(Ethylamino)-1-phenylbutan-1-on - 4-Ethylmethcathinon (4-EMC) 1-(4-Ethylphenyl)-2-(methylamino)propan-1-on Ethylmethylthiambuten - (Ethyl)(methyl)(1-methyl-3 , 3-di-2-thienylallyl) azan - Ethylon (bk-MDEA, MDEC) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-on - Ethylpiperidylbenzilat (1-ethyl-3-piperidyl) benzilat Eticyclidin PCE (Ethyl(1-phenylcyclohexyl)azan Etonitazen - {2-[2-(4-Ethoxybenzyl)-5-nitrobenzimidazol-1-yl]ethyl}diethylazan Etoxeridine - Ethyl{1-[2-(2-hydroxyethoxy)ethyl]-4-phenylpiperidin-4-carboxylat} Etryptamin α-Ethyltryptamin 1-(Indol-3-yl)butan-2-ylazan - FLEA N-[1-(1,3-Benzodioxol-5-yl)propan-2-yl]-N-methyl-hydroxylamin - 4-Fluoramfetamin (4-FA, 4-FMP) (RS)-1-(4-Fluorphenyl)propan-2-amin - ρ - Fluorfentanyl N-(4-Fluorphenyl)-N-(1-phenethyl-4-piperidyl)propanamid - 2-Fluormethamfetamin (2-FMA) 1-(2-Fluorphenyl)-N-methylpropan-2-amin - 3 [Fluormethamfetamin (3-FMA) 1-(3-Fluorphenyl)-N-methylpropan-2-amin Furethidin - ethyl {4-phenyl-1-[(2-tetra-hydrofurfuryloxy) ethyl] piperidin-4-carboxylate} - heroin (Diamorphine, Diacetylmorphin) - excluding diamorphine for the purposes referred to in annexes II and III - [(5R,6S)-4,5-Epoxy-17-methyl-morphin-7-en-3,6-diyl]diacetat Hydromorphinol 14 Hydroxydihydromorphin 4, 5α-epoxy-17-methyl-morph-Ibrahim 3, 6α, 14-triol - N-Hydroxyamfetamin (NOHA) N-(1-Phenylpropan-2-yl)hydroxylamin - ß Hydroxyfentanyl N-[1-(2-Hydroxy-2-phenyl-ethyl)-4-piperidyl]-N-phenylpropanamid - Hydroxymethylendioxyamfetamin (N-hydroxy MDA, MDOH) N-[1-(1,3-Benzodioxol-5-yl) propan-2-yl] hydroxylamin - β-hydroxy-3-methyl-fentanyl (Ohmefentanyl) N-[1-(2-Hydroxy-2-phenyl-ethyl)-3-methyl-4-piperidyl]-N-phenylpropanamid Hydroxypethidine - ethyl [4-(3) (hydroxyphenyl)-1-methyl 4-carboxylate] - 25I-NBOMe (2C-I-NBOMe) 2-(4-lod-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamin Lefetamin SPA [(R)-1,2-Diphenylethyl]dimethylazan levomethorphan - (9R,13R,14R)-3-Methoxy-17-methylmorphinan Levophenacylmorphan - 2-[(9R,13R,14R)-3-Hydroxy-morphinan-17-yl]-1-phenyl-ethanon Lofentanil - Methyl[(3R,4S)-3-methyl-1-phenethyl-4-(N-phenyl-propanamido)piperidin-4-carboxylat] LSD N, N-Diethyl-D-lysergamid (LSD, LSD-25) N, N-Diethyl-6-methyl-9,10-didehydroergolin 8beta carboxamide - times 3,5-Dimethoxy-4-(2-methyl-allyloxy)phenethylazan - MBDB-[1-(1,3-Benzodioxol-5-yl)butan-2-yl](methyl)azan - Mebroqualon 3-(2-Bromphenyl)2-methyl-chinazolin-4(3H)-on Mecloqualone - 3-(2-Chlorphenyl)-2-methyl-chinazolin-4() 3H)-on - mescaline 3,4,5-Trimethoxyphenethylazan Metazocine - 3,6,11-Trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol - methcathinone (Ephedron) 2-methylamino-1-phenyl propane 1-on - Methiopropamin (MPA) N-Methyl-1-(thiophen-2-yl)propan-2-amin - Methoxetamin (MXE) 2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexanon - Methoxyamfetamin (PMA) 1-(4-Methoxyphenyl)propan-2-ylazan - 5-methoxy-N, N-diisopropyltryptamin (5-MeO-DIPT) Diisopropyl[2-(5-methoxyindol-3-yl)ethyl]azan - 5-MEO-DMT (5-MeO-DMT) [2-(5-Methoxyindol-3-yl)ethyl]dimethylazan - (2-Methoxyethyl)(1-phenyl-cyclohexyl)azan - Methoxymetamfetamin (PMMA) [1-(4-Methoxyphenyl)propan-2-yl](methyl)azan - Methoxymethylendioxyamfetamin (MMDA) 1-(7-Methoxy-1) , 3-benzodioxole-5-yl) propan-2-ylazan - (3-Methoxypropyl)(1-phenyl-cyclohexyl)azan - Methylaminorex (4-Methylaminorex) 4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-ylazan-4-Methylbuphedron (4-MeMABP) 2-(Methylamino)-1-(4-methylphenyl)butan-1-on Methyldesorphin - 4, 5α-epoxy-6.17-dimethyl morphine 6-en-3-ol Methyldihydromorphin - 4, 5α-epoxy 6.17 dimethyl-morph-Ibrahim 3, 6α-dihydroxy - Methylendioxyethylamfetamin (N-ethyl MDA, MDE, MDEA) [1-(1,3-Benzodioxol-5-yl)propan-2-yl](ethyl)azan - Methylendioxymetamfetamin (MDMA) [1-(1,3-Benzodioxol-5-yl)propan-2-yl](methyl)azan - α-methylfentanyl N-Phenyl-N-[1-(1-phenylpropan-2-yl)-4-piperidyl]propanamid - 3-methylfentanyl (Mefentanyl) N-(3-Methyl-1-phenethyl-4-piperidyl)-N-phenylpropanamid - Methylmethaqualon 3-(2,4-Dimethylphenyl)-2-methyl-chinazolin-4(3H)on - 3-Methylmethcathinone () 3-MMC) 2-(Methylamino)-1-(3-methylphenyl)propan-1-on-4 Methylmethcathinone (Mephedrone) 1-(4-Methylphenyl)-2-methylaminopropan-1-on - Methylphenylpropionoxypiperidin (MPPP) (1-methyl-4-phenyl-4-piperidyl) propionate - methyl-3-phenylpropylamin (1M-3PP) (Methyl)(3-phenylpropyl)azan - Methylphenyltetrahydropyridin (MPTP) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin - Methylpiperidylbenzilat (1-methyl-3-piperidyl) benzilat-4-Methylthioamfetamin (4-MTA) 1-[4-(Methylsulfanyl)phenyl]propan-2-ylazan - α - Methylthiofentanyl N-Phenyl-N-{1-[1-(2-thienyl)propan-2-yl]-4-piperidyl}propanamid - 3-Methylthiofentanyl N-{3-Methyl-1-[2-(2-thienyl)ethyl]-4-piperidyl}-N-phenyl-propanamid - α Methyltryptamine (α-MT) 1-(Indol-3-yl)propan-2-ylazan Metopon 5-Methyldihydromorphinon 4, 5α-epoxy-3-hydroxy-5 ,17-dimethylmorphinan-6-on
Morpheridin
-
Ethyl(1-(2-morpholinoethyl)-4-phenylpiperidin-4-carboxylat)
-
Morphin-N-oxid
(5R,6S)-4,5-Epoxy-3,6-dihydroxy-17-methylmorphin-7-en-17-oxid
Myrophin
Myristylbenzylmorphin
(3-Benzyloxy-4,5α-epoxy-17-methylmorphin-7-en-6-yl)tetradecanoat
Nicomorphin
3,6-Dinicotinoylmorphin
4,5α-Epoxy-17-methyl-morphin-7-en-3,6α-diyl)dinicotinat
Noracymethadol
-
(6-Methylamino-4,4-diphenyl-heptan-3-yl)acetat
Norcodein
N-Desmethylcodein
4,5α-Epoxy-3-methoxy-morphin-7-en-6α-ol
Norlevorphanol
(-)3-Hydroxymorphinan
(9R,13R,14R)-Morphinan-3-ol
Normorphin
Desmethylmorphin
4,5α-Epoxymorphin-7-en-3,6α-diol
Norpipanon
-
4,4-Diphenyl-6-piperidinohexan-3-on
-
Parahexyl
3-Hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ol
-
PCPr
(1-Phenylcyclohexyl)(propyl)azan
-
Pentylon
(bk-MBDP)
1-(1,3- Benzodioxol-5-yl)-2-(methylamino)pentan-1-on Phenadoxon-Phenampromid 6-Morpholino-4,4-diphenyl-heptan-3-on-N-Phenyl-N-(1-piperidinopropan-2-yl)propanamid Phenazocine-6,11-dimethyl-3-phenethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol phencyclidine PCP 1-(1-Phenylcyclohexyl)piperidin-Phenethylphenylacetoxypipederidin (PEPAP) (1-Phenethyl-4-phenyl-4-piperidyl) acetate-Phenethylphenyltetrahydropyridin (PEPTP) 1-Phenethyl-4-phenyl-1,2,3,6-tetrahydropyridin Phenpromethamin 1-methylamino-2-phenyl-propane (PPMA) (Methyl)(2-phenylpropyl)azan Phenomorphan-17-Phenethylmorphinan-3-ol Phenoperidine-ethyl [1-(3-hydroxy-3-phenyl-propyl)-4-phenylpiperidin-4-carboxylat] Piminodine-Ethyl[1-(3-anilinopropyl)-4-phenylpiperidin-4-carboxylat]-PPP 1-Phenyl-2-(pyrrolidin-1-yl)propan-1-on Proheptazine-(1,3-) (Dimethyl-4-phenylazepan-4-yl) propionate Properidine - Isopropyl(1-methyl-4-phenyl-piperidin-4-carboxylat) - Psilocin (Psilotsin) 3-(2-Dimethylaminoethyl)indol-4-ol - Psilocin-(ETH) 3-(2-Diethylaminoethyl)indol-4-ol psilocybin - [3-(2-Dimethylaminoethyl)indol-4-yl]dihydrogenphosphat - psilocybin-(ETH) [3-(2-Diethylaminoethyl)indol-4-yl]dihydrogenphosphat - 2-(Pyrrolidin-1-yl)-1-(p-tolyl)propan-1-on racemethorphan - (9RS,13RS,14RS)-3-Methoxy-17-methylmorphinan Rolicyclidin PHP (PCPy) 1-(1-Phenylcyclohexyl)pyrrolidin - Salvia divinorum (plant and plant parts) - Tenamfetamin Methylendioxyamfetamin (MDA) (RS)-1-(1,3-Benzodioxol-5-yl)propan-2-ylazan Tenocyclidine TCP 1-[1-(2-Thienyl)cyclohexyl]piperidin Tetrahydrocannabinols) , following isomers and their stereochemical variants:-Δ6a(10a)-Tetrahydrocannabinol (Δ6a(10a)-THC) 6,6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ol - Δ6a-tetrahydrocannabinol (THC-Δ6a) (9R,10aR)-6,6,9-Trimethyl-3-pentyl-8,9,10,10a-tetra-hydro-6H-benzo [c] chromen-1-ol(6aR,9R,10aR)-6,6,9-Trimethyl-3-pentyl-6a,9,10,10a-tetrahydro-6H-benzo[c] chromen-1-ol - Δ7-tetrahydrocannabinol (THC-Δ7) - Δ8-tetrahydrocannabinol (THC-Δ8) (6aR, 10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,10,10a-tetra-hydro-6H-benzo [c] chromen-1-ol(6aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,9-tetrahydro-6H-benzo[c]chromen-1-ol - Δ10-tetrahydrocannabinol (THC-Δ10) - Δ9(11)-Tetrahydrocannabinol (Δ9(11)-THC) (6aR) , 10aR)-6,6-dimethyl-9-methylene 3-pentyl-6a, 7, 8, 9, 10, 10a-hexahydro-6 H-benzo [c] chromen-1-ol - Thenylfentanyl N-Phenyl-N-(1-thenyl-4-piperidyl)propanamid - Thienoamfetamin
(Thiopropamin) 1-(Thiophen-2-yl)propan-2-amin - Thiofentanyl N-Phenyl-N-{1-[2-(2-thienyl)ethyl]-4-piperidyl}propanamid Trimeperidin - (1,2,5-Trimethyl-4-phenyl-4-piperidyl)propionat - Trimethoxyamfetamin (TMA) 1-(3,4,5-Trimethoxyphenyl)propan-2-ylazan - 2,4,5-Trimethoxyamfetamin (TMA-2) 1-(2,4,5-Trimethoxyphenyl)propan-2-ylazan - esters, ethers and molecular compounds of the substances listed in this annex, if they are not listed in a different system and the existence of such esters, ethers and molecule connections is possible;
-the salts of the substances listed in this annex, if the existence of such salts is possible;
-the preparations of the substances listed in this annex, if they are not a) without applied on or in the human or animal body to be, only diagnostic or analytical purposes and their content on one or more narcotic drugs each does not exceed 0.001 per cent or isotopenmodifiziert substances in preparations or b) are particularly excluded;
-the stereoisomers of the substances listed in this or any other system if improperly used as narcotic drugs should be;
-Substances pursuant to section 2 paragraph 1 number 1 letter b to d with substances listed in this or any other system as well as the reproduction or extraction of substances according to § 2 para 1 number 1 letter of b biological materials suitable to (d), if an abuse for noise purposes is provided.

Annex II (to § 1 para 1) (traffic-enabled, but incapable of prescribing narcotics) (site: Federal Law Gazette I 2001, 1187-1189; regarding the details of the changes see footnote) column 1 contains the International Nonproprietary name (INN) of the World Health Organization. Designation of the substance, the INN takes precedence over all other labels.
Column 2 contains other non-protected fabric labels (short names or common names). If there exists no INN for a substance, the name bold in this column can be used to its unique name. All other non-bold-printed labels are scientifically inconclusive. They are therefore used in conjunction with the name in column 3.
Column 3 contains the chemical name of the substance according to the nomenclature of the International Union of pure and applied chemistry (IUPAC). If no name is listed in column 1 or 2, the column 3 is to use.
 
INN other non-proprietary or common name chemical name (IUPAC) - AB-CHMINACA N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazol-3-carboxamid - up FUBINACA n (1-amino-3-methyl-1-oxobutan-2-yl)-1-[(4-fluorphenyl)methyl]-1H-indazole 3-carboxamide off PINACA N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1 H indazole 3-carboxamide - 1-Adamantyl(1-pentyl-1H-indol-3-yl)methanon (Adamantan-1-yl)(1-pentyl-1H-indol-3-yl)methanon - AH-7921 (Doxylam) 3,4-Dichlor-N-{[1-(dimethylamino) cyclohexyl] methyl} Benzamide - AKB-48 (APINACA) N-(Adamantan-1-yl)-1-pentyl-1H-indazol-3-carboxamid - AKB-48F N-(Adamantan-1-yl)-1-(5-fluorpentyl)-1H-indazol-3-carboxamid - [1-(5-Fluorpentyl)-1H-indol-3-yl](2-iodphenyl)methanon AM-694 - AM-1220 {1-[(1-Methylpiperidin-2-yl)) methyl]-1h-indol-3-YL}(naphthalin-1-YL)methanon - AM-1220 Azepan [1-(1-Methylazepan-3-yl)-1H-indol-3-yl](naphthalin-1-yl)methanon - AM-2201 [1-(5-Fluorpentyl)-1H-indol-3-yl] (naphthalene-1-yl) methanon - AM-2232 5-[3-(Naphthalin-1-carbonyl)-1H-indol-1-yl]pentannitril - AM-2233 (2-Iodphenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanon Amfetaminil - (Phenyl)[(1-phenylpropan-2-yl)amino]acetonitril amineptine - 7-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylamino)heptansäure Aminorex 5-phenyl-4,5-dihydro-1,3-oxazol-2-ylazan - 5-APB-1-(Benzofuran-5-yl)propan-2-amin - 6-APB 1-(Benzofuran-6-yl)propan-2-amin - APICA (SDB-001 , 2NE1) N-(Adamantan-1-yl)-1-pentyl-1H-indole 3-carboxamide BB-22 (QUCHIC) Chinolin-8-yl[1-(cyclohexylmethyl)-1H-indol-3-carboxylat] - benzylpiperazine (BZP) 1-benzylpiperazine - Buphedron 2-(Methylamino)-1-phenylbutan-1-on butalbital 5-allyl-5-isobutylbarbitursäure - butobarbital 5-Butyl-5-ethylpyrimidin-2,4,6(1H,3H,5H)-trion - Butylon 1-(Benzo[d][1,3]dioxol-5-yl)-2-(methylamino)-1-butanone - cannabis (marijuana, plants and parts of plants belonging to the genus cannabis) - when intended for the manufacture of preparations for medical purposes are - ketobemidone Ketobemidon 1-[4-(3-Hydroxyphenyl)-1-methyl-4-piperidyl]propan-1-on - meta-Chlorphenylpiperazin (m-CPP) 1-(3-Chlorphenyl)piperazin - d cocaine methyl () 3ß-(benzoyloxy)tropan-2alpha-carboxylat) - CP 47,497 (cis-3-[4-(1,1-Dimethylheptyl)-2-hydroxyphenyl]-cyclohexanol) 5-(1,1-Dimethylheptyl)-2-[(1RS,3SR)-3-hydroxycyclohexyl]-phenol - CP 47,497-C6-Homolog(cis-3-[4-(1,1-Dimethylhexyl)-2-hydroxyphenyl]-cyclohexanol) 5-(1,1-Dimethylhexyl)-2-[(1RS,3SR)-3-hydroxycyclohexyl]-phenol - CP 47,497-C8-Homolog(cis-3-[4-(1,1-Dimethyloctyl)-2-hydroxyphenyl]-cyclohexanol) 5-(1,1-Dimethyloctyl)-2-[(1RS,3SR)-3-hydroxycyclohexyl]-phenol - CP 47,497-C9-Homolog(cis-3-[4-(1,1-Dimethylnonyl)-2-hydroxyphenyl]-cyclohexanol) 5-(1,1-Dimethylnonyl)-2-[(1RS (,3SR)-3-hydroxycyclohexyl]-phenol cyclobarbital - 5-(Cyclohex-1-en-1-yl)-5-ethylpyrimidin-2,4,6(1H,3H,5H)-trion - Desoxypipradrol (2-DPMP) 2-benzhydrylpiperidine - Dextromethadon (S) - 6-Dimethylamino-4,4-diphenylheptan-3-on Dextromoramide - (S)-3-Methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl)butan-1-on dextropropoxyphene - [(2S,3R)-4-Dimethylamino-3-methyl-1,2-diphenylbutan-2-yl]propionat - diamorphine [(5R,6S)-4,5-Epoxy-17-methylmorphin-7-en-3,6-diyl]diacetat - unless it provides for the production of preparations for medical purposes is - Difenoxin - 1-(3-Cyan-3) , 3-diphenylpropyl) - 4-phenylpiperidine 4 - carboxylic acid - except in preparations which calculated up to 0.5 mg Difenoxin, as a base, and, based on this amount, at least 5 per cent contain atropine sulphate - Dihydromorphin 4, without a further material of annexes I to III ever separated form 5α-epoxy-17-methyl-morph-Ibrahim 3, 6α-dihydroxy - Dihydrothebain 4, 5α-epoxy-3,6-dimethoxy-17-methyl-morphine 6-en-Dimethocain (DMC, Larocain) (3-Diethylamino-2,2-dimethylpropyl) - 4-aminobenzoate - 2,5-dimethoxy-4-iodamfetamin (DOI) 1-(4-Iodo-2) , 5-dimethoxyphenyl) propane 2-amino 3,4-Dimethylmethcathinon (3,4-DMMC) 1-(3,4-Dimethylphenyl)-2-(methylamino)propan-1-on diphenoxylate - Ethyl[1-(3-cyan-3,3-diphenylpropyl)-4-phenylpiperidin-4-carboxylat] - except in preparations that I to III up to 0.25 per cent or separated form up to 2.5 mg diphenoxylate, calculated as base, and, based on these quantities, at least 1 per cent contain atropine sulphate - without a further material of plants 4, 4'-Louisianajoe (para-methyl-4-methylaminorex) 4-Methyl-5-(4-methylphenyl)-4,5-dihydro-1 , 3-oxazol-2-amine-EAM-2201 (5-fluoro JWH-210) (4-Ethylnaphthalin-1-yl)[1-(5-fluorpentyl)-1H-indol-3-yl]methanon-benzoylecgonine 3ß-Hydroxytropan-2ß - carboxylic acid-Erythroxylum coca (plants and parts of plants the to the kind Erythroxylum coca-including the varieties bolivianum, spruceanum and novogranatense-non-plants)-Ethcathinon (RS)-2-(Ethylamino)-1-phenyl Propan-1-one Ethchlorvynol-1-chloro 3-ethylpent-1-en-4-in-3-ol Ethinamate-(1-Ethinylcyclohexyl) carbamate-3-O-ethyl morphine (ethylmorphine) 4, 5α-epoxy-3-ethoxy-17-methyl-morphine 7-en-6α-ol-except in preparations, the without one further fabric the plants I up III up to 2.5 by the hundred or ever split off form up to 100 mg ethyl morphine {[[, calculated as base, contain - Ethylphenidat Ethyl[2-(phenyl)-2-(piperidin-2-yl) acetate] Etilamfetamin N-ethyl amphetamine (Ethyl)(1-phenylpropan-2-yl)azan - 5F-ABICA (5F-AMBICA, 5-fluoro ABICA, 5-fluoro AMBICA) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluorpentyl)-1H-indol-3-carboxamid - 5F-AB-PINACA (5-fluoro AB-PINACA) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluorpentyl)-1H-indazol-3-carboxamid - 5F-AMB (5-fluoro AMB) Methyl{2-[1-(5-fluorpentyl)-1H-indazol-3-carboxamido]-3-methylbutanoat} - FDU-PB-22 Naphthalin-1-yl{1[(4-fluorphenyl)methyl]-1H-indol-3-carboxylat} Fencamfamin - N-ethyl-3-phenylbicyclo [2.2.1] heptan-2-amino - Flephedron (4-Fluormethcathinon , 4-FMC) 1-(4-Fluorphenyl)-2-(methylamino)propan-1-on - 4-Fluormethamfetamin (4-FMA) 1-(4-Fluorphenyl)-N-methylpropan-2-amin-3 Fluormethcathinon (3-FMC) 1-(3-Fluorphenyl)-2-(methylamino)propan-1-on - 5-Fluorpentyl-JWH-122 (MAM-2201) [1-(5-Fluorpentyl)-1H-indol-3-yl] (4-methyl naphthalene-1-yl) methanon-p-Fluorphenylpiperazin (p-FPP) 1-(4-Fluorphenyl)piperazin - 4-Fluortropacocain 3-(4-Fluorbenzoyloxy)tropan - 5-fluoro-UR-144 (XLR-11) [1-(5-Fluorpentyl)-1H-indol-3-yl] (2,2,3,3-tetramethylcyclopropyl) methanon - 5F-PB-22 (5F-QUPIC) Chinolin-8-yl[1-(5-fluorpentyl)indol-3-carboxylat] - 5F-SDB-006 N-Benzyl-1-(5-fluorpentyl)-1H indol-3-carboxamid - foot-PB-22 Chinolin-8-yl{1-[(4-fluorphenyl)methyl]-1H-indol-3-carboxylat} Glutethimid - 3 Ethyl-3-phenylpiperazine 2,6 Dione - ISO codeine 4, 5α-epoxy-3-methoxy-17-methyl-morphine 7-en 6vpp ol ISO methadone - 6-dimethylamino-5-methyl-4,4-diphenylhexan-3-one - JWH-007 (2-Methyl-1-pentyl-1H-indol-3-yl)(naphthalin-1-yl)methanon - JWH-015 (2-Methyl-1-propyl-1H-indol-3-yl)(naphthalin-1-yl)methanon - JWH-018 (1-Pentyl-3-(1-naphthoyl)indol) (Naphthalin-1-yl)(1-pentyl-1H-indol-3-yl)methanon - JWH-019 (1-Hexyl-3-(1-naphthoyl)indol) (Naphthalin-1-yl)(1-hexyl-1H-indol-3-yl)methanon - JWH-073 (1-Butyl-3-(1-naphthoyl)indol) (Naphthalin-1-yl)(1-butyl-1H-indol-3-yl)methanon - JWH-081 (4-methoxy-naphthalene-1-yl)(1-pentyl-1H-indol-3-yl) methanon - JWH-122 (4-Methylnaphthalin-1-yl)(1-pentyl-1H-indol-3-yl)methanon - JWH-200 [1-(2-Morpholinoethyl)-1H-indol-3-yl](naphthalin-1-yl)methanon - JWH-203 2-(2-Chlorphenyl)-1-(1-pentyl-1H-indol-3-yl) ethanon - JWH-210
(4-ethyl naphthalene-1-yl) (1-pentyl-1 H-indol-3-yl) methanon - JWH-250 (1-Pentyl-3-(2-methoxy-phenylacetyl)indol) - JWH-251 2-(2-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanon - 2-(2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanon JWH 307 [5-(2-Fluorphenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalin-1-yl) methanon l-amphetamine Levamphetamin (R) - 1-phenyl-Propan-2-ylazan - Levmetamfetamin (Levometamfetamin) (R)-(Methyl)(1-phenylpropan-2-yl)azan Levomoramid - (R)-3-Methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl)butan-1-on Levorphanol - (9R,13R,14R)-17-Methylmorphinan-3-ol mazindol - 5-(4-Chlorphenyl)-2,5-dihydro-3H-imidazol[2,1-a]isoindol-5-ol Mefenorex - 3-Chlor-N-(1-phenylpropan-2-yl)propan-1-amin meprobamate - (2-methyl-2-propylpropan-1) , 3-diyl) dicarbamat Mesocarb - (Phenylcarbamoyl)[3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl]azanid Metamfetamin methamphetamine (2S)-N-Methyl-1-phenylpropan-2-amin (RS) - Metamfetamin Metamfetaminracemat (RS)-(Methyl)(1-phenylpropan-2-yl)azan - methadone intermediate (Premethadon) 4-dimethylamino-2,2-diphenylpentannitril n - 2-Methyl-3-(2-methylphenyl)chinazolin-4(3H)-on - Methedron (4-Methoxymethcathinon, PMMC) 1-(4-Methoxyphenyl)-2-(methylamino)propan-1-on-p Methoxyethylamfetamin (PMEA) N-Ethyl-1-(4-methoxyphenyl)propan-2-amin - 4-Methylamfetamin 1-(4-Methylphenyl)propan-2-amin - Methylbenzylpiperazin (MBZP) 1-benzyl-4-methylpiperazine 3,4 Methylenedioxypyrovalerone (MDPV) 1-(Benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-on - 4-Methylethcathinon (4-MEC) 2-(Ethylamino)-) 1-(4-methylphenyl)propan-1-on - Methylon (3,4 methylenedioxy N-methcathinon, MDMC) 1-(Benzo[d][1,3]dioxol-5-yl)-2-(methylamino)propan-1-on (RS, SR) - methylphenidate - Methyl[(RS;SR)(phenyl)(2-piperidyl)acetat] Methyprylon - 3.3-diethyl-5-methyl 2,4 Dione - poppy straw concentrate (the handling of plants and parts of plants of the species Papaver somniferum falling to the concentration of alkaloids material) Moramid intermediate (Premoramid) 3-methyl-4-morpholino-2,2 diphenylbutansäure - MT-45 1-Cyclohexyl-4-(1,2-diphenylethyl) piperazin - Naphyron (Naphthylpyrovaleron) 1-(Naphthalin-2-yl)-2-(pyrrolidin-1-yl)pentan-1-on Nico Codin 6-Nicotinoylcodein (4, 5α-epoxy-3-methoxy-17-methyl-morphine 7-en-6α-yl) nicotinat Nicodicodin 6-Nicotinoyldihydrocodein (4, 5α-epoxy-3-methoxy-17-methyl-morph-Ibrahim 6α-yl) nicotinate - oripavine
4, 5α-epoxy-6-methoxy-17-methylmorphina 6.8 dien-3-ol oxymorphone 14-Hydroxydihydromorphinon 4, 5α-epoxy-3,14-dihydroxy-17-methyl-morph-Ibrahim 6-on - Papaver bracteatum (plants and parts of plants, except the seeds of plants belonging to the species Papaver bracteatum) - except for ornamental purposes - PB-22 (QUPIC) Chinolin-8-yl(1-pentylindol-3-carboxylat) - Pentedron 2-(Methylamino)-1-phenylpentan-1-on - pethidine intermediate of A (Prepethidin) 1-methyl-4-phenylpiperidine 4-carbonitrile - pethidine intermediate B (Norpethidin) Ethyl(4-phenylpiperidin-4-carboxylat) - pethidine intermediate C (Pethidinsäure) 1-methyl-4-phenylpiperidine 4 - carboxylic acid Phendimetrazine - (2S,3S)-3,4-Dimethyl-2-phenylmorpholin Phenmetrazine - 3-phenyl - 2 - Methylmorpholine Pholcodine Morpholinylethylmorphin 4,5α-Epoxy-17-methyl-3-(2-morpholinoethoxy)morphin-7-en-6α-ol -
except in preparations, that without a further material of annexes I to III as a solution up to 0.15 per cent, depending on the packaging unit calculated as base, but not more than 150 mg, or ever separated form up to 20 mg of Pholcodine, Pyrovaleron - 2-(Pyrrolidin-1-yl)-1-(ρ-tolyl)pentan-1-on - α-Pyrrolidinovalerophenon (α-PVP) 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-on - propiram - N-(1-Piperidinopropan-2-yl)-N-(2-pyridyl)propanamid contain Racemoramide - (RS)-3-methyl-4-morpholino-2 ,2-diphenyl-1-(pyrrolidin-1-YL)Butan-1-on Racemorphan - (9RS,13RS,14RS)-17-Methylmorphinan-3-ol - RCS-4 (4-Methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanon - RCS-4 ortho-isomer (o-RCS-4) (2-Methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanon - N-benzyl-1-pentyl SDB-006-1 H-indol-3-carboxamid Butabarbital Butabarbital 5-(Butan-2-yl)-5-ethylpyrimidin-2,4,6(1H,3H,5H)-trion - STS-135 (5F-2NE1) N-(Adamantan-1-yl)-1-(5-fluorpentyl)-1H-indol-3-carboxamid - Δ9-tetrahydrocannabinol (THC-Δ9) 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol - Tetrahydrothebain 4, 5α-epoxy-3,6-dimethoxy-17-methyl morph Ibrahim Thebacon Acetyldihydrocodeinon (4, 5α-epoxy-3-methoxy-17-methyl-morphine 6-en-6-yl) acetate - thebaine 4, 5α-epoxy-3) , 6-dimethoxy-17-methylmorphina 6.8-dien - THJ-018 (JWH-018 analogue of Indazole) (naphthalene-1-yl)(1-pentyl-1H-indazol-3-yl) methanon - THJ-2201 (AM-2201 Indazol analogue) [1-(5-Fluorpentyl)-1H-indazol-3-yl] (naphthalene-1-yl) methanon cis Tilidine - Ethyl[(1RS,2RS)-2-dimethylamino-1-phenylcyclohex-3-encarboxylat]-3 Trifluormethylphenylpiperazin (TFMPP) 1-[3-(Trifluormethyl)phenyl]piperazin - UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanon vinylbital - 5-Ethenyl-5-(pentan-2-yl)pyrimidin-2,4,6(1H,3H,5H)-trion zipeprol - 1-Methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol - esters , Ether and molecular compounds in this plant esters and ethers of substances listed in annex III, except gamma-hydroxybutyric acid (GHB), if they are not listed in a different system and the existence of such esters, ethers and molecule connections is possible.
-the salts of the substances listed in this annex, if the existence of such salts is possible, as well as the salts and molecular compounds of the substances listed in annex III, if the existence of such salts and molecular compounds, and they are applied not medical, dental or veterinary;
-the preparations of the substances listed in this annex, if not a) without applied on or in the human or animal body to be, only diagnostic or analytical purposes and their content on one or more narcotic drugs, Lyophilisates and appropriately to be used mixtures in the ready-made solution, each 0.01 per cent does not exceed or substances in preparations isotopenmodifiziert or b) are particularly excluded.

Annex III (to § 1 para 1) traffic-enabled and capable of prescribing Narcotics (site: Federal Law Gazette I 2001, 1189-1195; regarding the details of the changes cf. footnote) column 1 contains the International Nonproprietary name (INN) of the World Health Organization. Designation of the substance, the INN takes precedence over all other labels.
Column 2 contains other non-protected fabric labels (short names or common names). If there exists no INN for a substance, the name bold in this column can be used to its unique name. All other non-bold-printed labels are scientifically inconclusive. They are therefore used in conjunction with the name in column 3.
Column 3 contains the chemical name of the substance according to the nomenclature of the International Union of pure and applied chemistry (IUPAC). If no name is listed in column 1 or 2, the column 3 is to use.
 
INN other non-proprietary or common name chemical name (IUPAC) alfentanil - N-{1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-methoxymethyl-4-piperidyl}-N-phenylpropanamid Allorbarbital - 5,5 Diallylbarbitursäure alprazolam - 8-chloro-1-methyl-6-phenyl - 4 H-[1,2,4] triazolo [4,3-a] [1,4] benzodiazepine - taken out in preparations I to III ever separated form containing up to 1 mg alprazolam - without a further material of plants except in preparations without delay release Amfepramone diethylpropion 2-Diethylamino-1-phenyl propane 1-on - , without a further substance of annexes I to III ever separated form up to 22 mg, and in preparations delayed-release, which calculates up to 64 mg diethylpropion, as base, without a further material of annexes I to III ever separated form contain - Amfetamin amphetamine (RS) - 1-phenyl-Propan-2-ylazan amobarbital - 5-ethyl-5-isopentylbarbitursäure barbital-5,5 diethylbarbituric acid - except in preparations, a) without a further material of annexes I to III up to 10 per cent or b) without on the or to be applied in the human or animal body, only diagnostic or analytical purposes serve and without a further material of plants I to III per packing unit, not more than 25 g of barbital, calculated as acid containing - Bromazepam - 7-Brom-5-(2-pyridyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-on - except in preparations without a further material of plants I to III ever separated form containing up to 6 mg of Bromazepam - Brotizolam - 2-Brom-4-(2-chlorphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][ 1,4] diazepin - except in preparations containing up to 0.25 mg Brotizolam without a further material of annexes I to III up to 0.02 per cent or separated form - buprenorphine - (5R,6R,7R,14S)-17-Cyclopropyl-methyl-4,5-epoxy-7-[(S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-6,14-ethanomorphinan-3-ol camazepam - (7-Chlor-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-enzodiazepin-3-yl)(dimethylcarbamat) - cannabis (marijuana, plants and parts of plants belonging to the genus cannabis) - only in preparations , which as a finished product are approved - Cathine (+)-norpseudoephedrine (D norpseudoephedrine) (1S,2S)-2-Amino-1-phenylpropan-1-ol - except in preparations which up to 40 mg of Cathine, calculated as base, without a further substance of appendixes I to III up to 5 per cent as a solution, but not more than 1 600 mg per packing unit or per separated form contain - chlordiazepoxide - 7-chloro-2-methylamino-5-phenyl-3 H-1,4-benzodiazepin - 4 - oxide)
except in preparations containing up to 25 mg chlordiazepoxide - Clobazam - 7-Chlor-1-methyl-5-phenyl-1,3-dihydro-2H-1,5-benzodiazepin-2,4(5H)-dion - except in preparations, without a further material of annexes I to III ever separated form, up to 30 mg of Clobazam contain the form ever separated without a further material of annexes I to III - Clonazepam - 5-(2-Chlorphenyl)-7-nitro-1,3-dihydro-2H-1 , 4-benzodiazepin-2-one - except in preparations up to 2 mg Clonazepam containing without a further material of annexes I to III up to 0.25 per cent as a solution, but not more than 250 mg per packing unit or per separated form - clorazepate - (RS) - 7-chloro 2-oxo-5-phenyl-2,3-dihydro - 1 H-1,4-benzodiazepin-3 - carboxylic acid - except in preparations, the form ever separated without a further material of annexes I to III up to 50 mg , as solids for parenteral use only contain up to 100 mg, clorazepate DIPOTASSIUM salt as a cocaine (Benzoylecgoninmethylester) - Clotiazepam - 5-(2-Chlorphenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-on - except in preparations without a further material of annexes I to III ever separated form containing up to 20 mg Clotiazepam - Cloxazolam - 10-Chlor-11b-(2-chlorphenyl)-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-on - Methyl[3ß-(benzoyloxy)tropan-2ß-carboxylat] - codeine (3-methyl-morphine) 4, 5α-epoxy-3-methoxy-17-methyl-morphine 7-en-6α-ol - except in preparations , that without a further material of plants I to III up to 2.5 per cent or separated form up to 100 mg codeine, calculated as base, contain. For exempt preparations prescribed for betäubungsmittel - or fragmented people, however, apply the rules on prescribing and dispensing of narcotic drugs. -Delorazepam - 7-Chlor-5-(2-chlorphenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-on Dexamfetamin Dexamphetamin (S) - 1-phenyl-Propan-2-ylazan Dexmethylphenidate - Methyl[(R,R)(phenyl)(2-piperidyl)acetat] - diamorphine [(5R,6S)-4,5-Epoxy-17-methylmorphin-7-en-3,6-diyl]diacetat - only in preparations that are approved for substitution treatment - diazepam - 7-chloro 1-methyl-5-phenyl-1,3-dihydro - 2 H-1,4-benzodiazepin-2-one - without a further substance of appendixes I to III up to 1 per cent as a syrup or drip solution except in preparations, , but not more than 250 mg per packing unit, or separated form up to 10 mg of diazepam include - dihydrocodeine - 4, 5α-epoxy-3-methoxy-17-methyl-morph-Ibrahim 6α-ol - except in preparations I to III up to 2.5 per cent or separated form calculated as base, containing up to 100 mg of dihydrocodeine, without a further material of plants. For exempt preparations prescribed for betäubungsmittel - or fragmented people, however, apply the rules on prescribing and dispensing of narcotic drugs. -Dronabinol -, (6aR, 10aR) - 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo [c] chromen-1-ol estazolam - 8-chloro-6-phenyl - 4 H-[1,2,4] triazolo [4,3-a] benzodiazepin - except in preparations containing up to 2 mg of estazolam - ethyl loflazepate - Ethyl[7-chlor-5-(2-fluorphenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-carboxylat] without a further material of annexes I to III ever separated form Etizolam - 4-(2-Chlorphenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin Etorphine - (5R ,6R,7R,14R)-4,5-epoxy-7-[(R)-2-hydroxypentan-2-yl]-6-methoxy-17-methyl-6,14-ethenomorphinan-3-OL Fenethylline - 1,3-Dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]-3,7-dihydro-2H-purin-2,6(1H)-dion Fenproporex - (RS)-3-(1-Phenylpropan-2-ylamino)propannitril - except in preparations which up to 11 mg Fenproporex, calculated as base, without a further material of annexes I to III ever separated form contain fludiazepam - 7-Chlor-5-(2-fluorphenyl)-1-methyl-1 - fentanyl - N-(1-Phenethyl-4-piperidyl)-N-phenylpropanamid , 3-dihydro-2 H-1,4-benzodiazepin-2-on flunitrazepam - 5-(2-Fluorphenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-on halazepam - 7-Chlor-5-phenyl-1-(2,2,2-trifluorethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-on - Flurazepam - 7-Chlor-1-(2-diethylaminoethyl)-5-(2-fluorphenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-on - except in preparations I to III ever separated form containing up to 30 mg of Flurazepam - without a further material of plants except in preparations containing up to 120 mg halazepam the form ever separated without a further material of annexes I to III - Haloxazolam -.
10-Brom-11B-(2-fluorphenyl)-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-on hydrocodone Dihydrocodeinon 4, 5α-epoxy-3-methoxy-17-methyl-morph-Ibrahim 6-on Hydromorphone Dihydromorphinon 4, 5α-epoxy-3-hydroxy-17-methyl-morph-Ibrahim 6-on-γ-hydroxy butyric acid (GHB) 4-hydroxy butane acid without a further substance of appendixes I except in preparations for injection, until III up to 20 per cent and separated form up to 2 g of Gamma hydroxy butyric acid, calculated as acid, include - Ketazolam - 11-chloro-2,8-dimethyl-12 b-phenyl-8 ,12B-dihydro-4H-[1,3]oxazino[(3,2-d][1,4]benzodiazepin-4,7(6H)-Dion - except in preparations which up to 45 mg Ketazolam contain without a further material of annexes I to III separated form - Levacetylmethadol Levomethadylacetat (LAAM) [(3S,6S)-6-Dimethylamino-4,4-diphenylheptan-3-yl] acetate Levomethadon - (R) - 6-Dimethylamino-4,4-diphenylheptan-3-on Lisdexamfetamin - (2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamid Loprazolam - 6-(2-Chlorphenyl)-2-[(Z)-4-methylpiperazin-1-ylmethylen]-8-nitro-2 , 4-dihydro-1 H-imidazo [1,2-a] [1,4] benzodiazepin-1-one - except in preparations without a further material of plants I to III ever separated form containing up to 2.5 mg of Loprazolam - lorazepam - (RS)-7-Chlor-5-(2-chlorphenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-on - except in preparations containing up to 2.5 mg of lorazepam the form ever separated without a further material of annexes I to III - lormetazepam - 7-Chlor-5-(2-chlorphenyl)-3-hydroxy-1-methyl-1 , 3-dihydro-2 H-1,4-benzodiazepin-2-one - except in preparations, without a further material of annexes I to III ever separated form up to 2 mg of lormetazepam contain - medazepam - 7-chloro-1-methyl-5-phenyl-2,3-dihydro-1 H-1,4 benzodiazepine - taken out in preparations that contain up to 10 mg of medazepam without a further material of annexes I to III separated form - methadone - (RS) - 6-Dimethylamino-4,4-diphenylheptan-3-on methylphenidate - methyl [(RS; RS)(phenyl)(2-piperidyl)acetat] methylphenobarbital Mephobarbital (RS) - 5-ethyl-1-methyl-5-phenyl barbituric acid - except in preparations which calculates up to 200 mg methylphenobarbital, as acidity, without a further material of annexes I to III ever separated form without any additional substance contain - Midazolam - 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin - except in preparations, the annexes I to III up to 0.2 per cent or separated form contain up to 15 mg of Midazolam - morphine (5R , 6S)-4,5-Epoxy-17-methyl-morphin-7-en-3,6-diol Nabilone - (6aRS,10aRS)-1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-on nimetazepam - 1-methyl-7-nitro-5-phenyl-1,3-dihydro-2 H-1,4-benzodiazepin-2-one nitrazepam - 7-Nitro-5-phenyl-1,3-dihydro-2 H-1,4-benzodiazepin-2-one - except in preparations, the form ever separated without a further material of must I to III up to 0.5 per cent as a solution, but not more than 250 mg per packing unit , or ever separated form up to 10 mg of nitrazepam - nordazepam - 7-chloro-5-phenyl-1,3-dihydro-2 H-1,4-benzodiazepin-2-one - except in preparations, that without a further material of the annexes I to III ever separated form up to 0.5 per cent as a solution, but not more than 150 mg per packing unit, or separated form contain up to 15 mg of nordazepam - Normethadone - 6-Dimethylamino-4 , 4-diphenyl-hexan-3-one - opium (the coagulated juice of plants belonging to the species Papaver somniferum) - except in preparations, which are manufactured according to a process engineering in the homeopathic part of the Pharmacopoeia, if the final concentration does not exceed the sixth decimal potency - oxazepam - 7-chloro 3-hydroxy-5-phenyl-1,3-dihydro-2 H-1,4-benzo-diazepin-2-one - except in preparations which up to 50 mg oxazepam contain without a further material of annexes I to III separated form - Oxazolam - (2RS ,11bSR)-10-chlor-2-methyl-11b-phenyl-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-on - except in preparations I to III ever separated form containing up to 20 mg of Oxazolam - without a further material of the facilities OxyContin 14-Hydroxydihydrocodeinon 4, 5α-epoxy-14-hydroxy-3-methoxy-17-methyl-morph-Ibrahim 6-on - Papaver somniferum (plants and parts of plants, except the seeds, of belonging to the species Papaver somniferum (including the subspecies setigerum) plants) - except when the traffic with them (except growing) for ornamental purposes is used and if in the dried state 0.02 per cent morphine content does not exceed; in this case, the narcotics legislation to be applied to the import, export, and transit - except in preparations, which are manufactured according to a process engineering in the homeopathic part of the Pharmacopoeia, if the final concentration does not exceed the fourth decimal potency - find
except in preparations, that without a further material of annexes I to III up to 0.015 per cent calculated as base, containing morphine, and are composed of one or more other ingredients in such a way, that the narcotic drugs not through easy to use procedure, or to an extent that endangers the public health can be recovered - Pemolin - 2-imino-5-phenyl-1,3-oxazolidin-4-on - except in preparations , calculated up to 20 mg of Pemolin, without a further material of annexes I to III ever separated form as a base, contain - Pentazocine - (2R,6R,11R)-6,11-Dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol pentobarbital - (RS)-5-Ethyl-5-(pentan-2-yl)barbitursäure - Ethyl(1-methyl-4-phenyl-piperidin-4-carboxylat) - Phenazepam 7-Brom-5-(2-chlorphenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-on pethidine phenobarbital - 5-ethyl-5 - phenyl barbituric acid - without a further substance of appendixes I to III up to 10 per cent or separated form except in preparations, up to 300 mg of phenobarbital, calculated as acid, contain - phentermine - 2-benzyl-propane 2-ylazan - except in preparations which calculates up to 15 mg phentermine, as base, without a further material of annexes I to III ever separated form Pipradrol - pinazepam - 7-Chlor-5-phenyl-1-(prop-2-in1-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-on - Diphenyl(2-piperidyl)methanol Piritramide - 1'-(3-Cyan-3,3-diphenylpropyl)[1,4'-bipiperidin]-4'-carboxamid prazepam - 7-chloro-1-cyclopropylmethyl-5-phenyl-1,3-dihydro-2 H-1 , 4-benzodiazepin-2-one - except in preparations that contain up to 20 mg of prazepam without a further material of annexes I to III separated form - remifentanil - Methyl{3-[4-methoxycarbonyl-4-(N-phenylpropanamido)piperidino]propanoat} secobarbital - 5-Allyl-5-(pentan-2-yl)barbitursäure sufentanil - N-{4-Methoxymethyl-1-[2-(2-thienyl)ethyl]-4-piperidyl}-N-phenylpropanamid Tapentadol - 3-[(2R,3R)-1-Dimethylamino-2-methylpentan-3-yl]phenol temazepam - (RS) - 7-chloro 3-hydroxy-1-methyl-5-phenyl-1,3-dihydro - 2 H-1 , Tilidine trans Tilidine Ethyl[(1RS,2SR)-2-dimethyl-amino-1-phenylcyclohex-3-encarboxylat] - 4-benzodiazepin-2-one - except in preparations without a further material of annexes I to III up to 20 mg temazepam containing the split form - tetrazepam - 7-Chlor-5-(cyclohex-1-enyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-on - except in preparations I to III ever separated form containing up to 100 mg of tetrazepam - without a further material of plants except in solid preparations delayed-release , the form ever separated without a further material of annexes I to III up to 300 mg of Tilidine, calculated as base, and, based on this amount, at least 7.5 per cent contain Naloxonhydrochlorid - triazolam - 8-Chlor-6-(2-chlorphenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin - except in preparations containing the form ever separated without a further material of annexes I to III up to 025 mg triazolam - zolpidem - N ,N-dimethyl-2-[6-methyl-2-(p-toly)imidazo[1,2-a]pyridin-3-YL]acetamid - except in preparations for oral use, that without a further material of annexes I to III ever separated form up to 8.5 mg zolpidem, contain calculated as base, - the salts and molecular compounds of the substances listed in this annex, if they according to the findings of medical science are applied medical, dental or veterinary;
-the preparations of the substances listed in this annex, if they are not a) without on or in the human or animal body to be used, only diagnostic which analytical purposes and does not exceed her salary at one or more narcotic drugs, Lyophilisates and appropriately to be used mixtures in the ready-made solution, each 0.01 per cent or that substances in preparations isotopenmodifiziert or b) are particularly excluded. However, the narcotics regulations on the import, export and transit apply for exempt preparations - except those with codeine or dihydrocodeine. Preparations exempted according to point (b) the position of barbital can be however, one without authorization pursuant to section 11 of the Narcotic Drugs Act -, or carried out, if not to fear misuse according to the circumstances.